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ABSTRACT 
The degeneration of midbrain dopaminergic (mDA) neurons accounts for some of the main 
motor symptoms of Parkinson’s disease (PD). Efforts during the last decades have focused on 
understanding how mDA neurons are generated and maintained with the hope of developing 
novel stem cell-based replacement therapies. In this thesis, I address some of these questions 
in four papers.    
Paper I: Wnt signaling controls multiple developmental processes in the embryo. Here we 
report that Wnt1 deletion causes the loss of Lmx1a and Ngn2 expression in the midbrain floor-
plate resulting in the loss of mDA progenitor specification and neurogenesis in this region. 
Only a few ectopic LMX1A+, NURR1+ and TH+ cells were transiently found in the basal plate. 
This phenotype and the morphogenesis defect found in Wnt5a−/− mice were worsened in 
Wnt1−/−;Wnt5a−/− mice, indicating the existence of a previously unsuspected cooperation 
between Wnt1 and Wnt5a in mDA neuron development in vivo. Based on these results, we 
developed a combined Wnt protocol to promote the generation of mDA neurons from neural 
and embryonic stem cells in vitro. We conclude that coordinated Wnt actions promote mDA 
neuron development in vivo and in stem cells. 
Paper II: In this study we report that the chemokine Cxcl12 is expressed in the meninges, 
surrounding the ventral midbrain (VM) and that its cognate receptor CXCR4, is present and 
activated in NURR1+ mDA precursors and neurons. We found that VM meninges or CXCL12 
promoted migration and neuritogenesis of TH+ cells in a CXCR4-dependent manner in vitro. 
Consistently, pharmacological blockade of CXCR4 or genetic deletion of Cxcr4 resulted in an 
accumulation of TH+ cells in the lateral aspect of the intermediate zone in the VM. Moreover, 
the processes of TH+ cells in Cxcr4−/− mice were no longer radially distributed but disoriented. 
Thus our results indicate that CXCL12/CXCR4 regulate the radial migration of mDA neurons. 
Paper III: We report that the homeodomain transcription factor ZEB2, is present at a high level 
in progenitor cells of the ventricular zone in the midbrain floor plate and that its expression 
diminishes in NURR1+ post-mitotic precursors. We found that ZEB2 upregulated miR200c, 
which in turn repressed Zeb2, to form a negative feedback loop. Overexpression of Zeb2 
reduced the levels of CXCR4 and NR4A2 in the developing VM in vivo, resulting in migration 
and mDA differentiation defects. This phenotype was phenocopied by mir200c knockdown, 
indicating that the Zeb2-miR200c loop prevents the premature differentiation of mDA 
progenitors into postmitotic cells and their migration. 
Paper IV: We demonstrate that the extracellular matrix protein, laminin 511 (LM511), 
promotes midbrain dopaminergic neuron survival and differentiation via binding to integrin 
α3β1 and activation of the Yes-Associated protein, YAP. We found that LM511-YAP enhances 
mDA neuron survival by inducing the expression of miR-130a, which reduces the levels of 
PTEN, a negative regulator of the Akt/PKB pro-survival pathway, both in vitro and in vivo. 
Additionally, YAP up-regulates the expression of mDA differentiation genes such as LMX1A, 
LMX1B and PITX3, and prevents the loss of mDA neurons by oxidative stress. Thus our results 
suggest the LM511-YAP pathway as a possible target for the development of novel therapies 
for PD.  
In sum, the data presented in this thesis provide evidence that multiple factors control common 
aspects of mDA development such as neurogenesis, positively controlled by WNT1, WNT5A 
and miR200c and negatively by ZEB2. Similarly, the migration of mDA neurons is controlled 
by WNT5A, miR200c and CXCL12/CXCR4. Lastly, we found that the survival and 
differentiation of mDA neurons is not only controlled by neurotrophic factors, but also by the 
extracellular molecule, LM511, via YAP activation.   
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1 INTRODUCTION 
1.1 PARKINSON’S DISEASE AND CELL REPLACEMENT THERAPY 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting approximately 
1% of the population over 65 years of age per year, with some variation depending on ethnicity 
and gender (Van Den Eeden et al., 2003; Wijeyekoon and Barker, 2009). The major symptoms 
of PD include bradykinesia, rigidity and a resting tremor (Kalia and Lang, 2015). At 
pathological level, the main features of PD include the loss of midbrain dopaminergic (mDA) 
neurons within substantia nigra pars compacta (SNc) and the presence of Lewy bodies, cellular 
aggregates formed by alpha-synuclein and other misfolded proteins. The cause of mDA neuron 
death is still not understood, but oxidative stress, alterations in autophagosome and proteasome 
systems, inflammation, and genetic factors have been shown to be involved (Eriksen et al., 
2005; Miller et al., 2009; Tansey et al., 2007). Multiple genes and loci have been associated 
with PD, including causal mutations (SNCA, PARK2, CHCHD2, LRRK2, VPS13C, VPS35, 
FBXO7, PLA2G6, PARK7, ATP13A2 and, PINK1) (Bonifati, 2014; Klein and Westenberger, 
2012; Singleton and Hardy, 2016).  
PD patients are currently treated with pharmacological tools (mainly L-DOPA and 
dopaminergic agonists) or surgery, such as deep brain stimulation. These treatments relieve the 
motor symptoms of PD (Hickey and Stacy, 2016; Smulders et al., 2016; Verhagen Metman et 
al., 2016), but they neither address the cause of disease nor do they replace the mDA neurons 
lost by disease. As a consequence, disease progresses and mDA neurons continue to 
degenerate, making therapies less effective. In advanced phases of disease, patients experience 
motor complications, as well as no-motor symptoms, including depression and dementia. 
Patients suffering PD end up experiencing progressive disability and reduced quality of life 
(Kalia and Lang, 2015). As PD progresses, the cost of the illness escalates, placing an economic 
burden on the healthcare system, society and patients themselves (Findley, 2007). 
Proof of concept of cell replacement therapy (CRT) for PD has been provided by a series of 
studies in PD patients with intrastriatal grafts using human fetal ventral mesencephalic (hfVM) 
tissue (Barker et al., 2013; Barker et al., 2015; Lindvall and al., 1989; Lindvall et al., 1988). 
Grafted mDA neurons are known to innervate correct target cells in the host striatum 
(Kordower et al., 1995) and the patient’s motor symptoms improve in some cases for as long 
as 16 years after transplantation (Politis et al., 2010). However logistic and ethical issues have 
hampered the wide use of hfVM in the clinic. In addition, variability in the quality of the tissue 
preparation causes variation in the number and types of cells within the preparations, leading 
to variable results and side effects. One such adverse effect is graft-induced dyskinesia, which 
is thought to be due to contamination of the midbrain tissue with serotonergic neurons from the 
hindbrain (Lindvall and Björklund, 2011; Politis et al., 2010). Recent advancements in stem 
cell and developmental biology have allowed to obtain high quality mDA neurons from human 
embryonic stem (hES) cells (Kirkeby et al., 2012; Kriks et al., 2011). These cell preparations 
have emerged as a promising cell source for transplantation as they can be readily generated 
 2 
and characterized prior to clinical application (Arenas, 2002; Arenas, 2010; Arenas et al., 2015; 
Barker et al., 2015; Politis and Lindvall, 2012). 
1.2 STEM CELLS 
Stem cells are defined as cells that have the ability to continuously self-renew and give rise to 
differentiated progeny. Stem cells can be classified according to their origin (embryonic or 
adult) or their potential. Monopotent, such as adult hippocampal stem cells that can only give 
rise to neurons.  Multipotent, cells that can give rise to all cell types in a tissue, such as long 
term neuroepithelial stem (lt-NES) cells derived from hES cells or fetal tissue, which are 
capable of giving rise to diverse types of neurons, astrocytes and oligodendrocytes (Falk et al., 
2012; Koch et al., 2009; Tailor et al., 2013). Finally, pluripotent stem cells, such as embryonic 
stem (ES) cells or induced pluripotent stem (iPS) cells, possess the ability to differentiate into 
all the cell types in an organism.  
1.2.1 Embryonic stem (ES) cells 
Mouse ES cells were the first to be derived from an organism, by cultivation of cells from the 
inner cell mass of blastocysts (Evans and Kaufman, 1981; Martin, 1981). These cells can be 
readily maintained and expanded as an undifferentiated pure cell population in vitro. Moreover, 
they can differentiate into every cell type in the body under appropriate conditions (Keller, 
1995; Keller, 2005). Similar properties have been described for human ES cell lines, which 
were established almost two decades later (Thomson et al., 1998).  
1.2.2 Differentiation of ES cells 
As mentioned above, one important characteristic of ES cells is their capacity to generate 
differentiated cell types belonging to the three germinal layers both in vivo (Bradley et al., 
1984) and in vitro (Keller, 1995; Smith, 2001). Protocols have been developed to differentiate 
ES cells to a broad spectrum of cell types including hematopoietic cells, cardiomyocytes, 
oligodendrocytes and pancreatic  cells (Keller, 1995; Murry and Keller, 2008).  Knowledge 
obtained from understanding normal development has facilitated the optimization of specific 
differentiation protocols, taking cells from gastrulation to the induction of endoderm, 
mesoderm and ectoderm and to their downstream derivatives. Moreover, neuralized human ES 
cells have been differentiated into mDA neurons in vitro by using appropriate developmental 
factors such as SHH and activation of Wnt signaling (Kirkeby et al., 2012; Kriks et al., 2011).               
                                                                                                                                                    
1.3 ADULT MIDBRAIN DOPAMINERGIC NEURONS 
Neurons capable of synthesizing the neurotransmitter dopamine, DA neurons, are distributed 
widely in the mammalian brain (Björklund and Dunnett, 2007). In the ventral midbrain (VM), 
three groups of mDA neurons, A8 (RrF), A9 (SNc) and A10 (VTA), compose the so-called 
mDA neurons. Of these, neurons in A9 (SNc) are the ones predominantly affected in PD 
patients.  
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Each mDA cell group is involved in the control and/or modulation of specific brain functions 
according to their distinct projection fields. DA neurons of the SNc innervate the striatum and 
form the nigrostriatal system that controls voluntary movement and body posture. The 
mesocortical and mesolimbic systems, originating in the A8 and A10 groups, are on the other 
hand involved in the modulation and control of cognitive and emotional/rewarding behaviors.  
 
1.4 MIDBRAIN DOPAMINERGIC NEURON DEVELOPMENT 
1.4.1 Neural induction and patterning 
During gastrulation, a single cell layer called blastula gives rise to a three-layered structure 
formed by the ectoderm in the outside, the mesoderm in the middle and the endoderm in the 
inside. The notochord then induces the overlaying ectoderm into the neuroectoderm, which 
forms the neural plate, a flat sheet of neuroepithelial cells. The early neural plate undergoes 
neurulation, the process by which the neural plate rolls up to form the neural tube, where the 
prospective brain and spinal cord originate. Subsequently, gradients of developmental signals 
in the dorsoventral and 
anteroposterior axis pattern the 
neural tube, provide regional 
identity to different segments of 
the neural tube.  The neural tube 
is partitioned along the 
dorsoventral axes under the 
influence of the underlying 
meso-endodermal tissue 
(ventral), as well as adjacent 
non-neural ectodermal 
structures (dorsal). Signals 
involved in this process include 
BMPs dorsally and SHH 
ventrally. These factors give rise 
from ventral to dorsal to the 
floor plate (FP), the basal plate 
(BP), the alar plate (AP) and the 
roof plate (RP) (Figure 1) 
(Wurst and Bally-Cuif, 2001).  
 
 
Another important signaling center for the patterning of the neural tube, is the isthmic organizer 
(IsO), which defines the midbrain-hindbrain boundary (MHB) (Joyner et al., 2000; Rhinn et 
 
Figure 1. Schematic showing mouse midbrain at E11.5. 
Midbrain dopaminergic neurons reside in the floor plate, 
which can be divided into three layers: ventricular zone (VZ), 
intermediate zone (IZ) and marginal zone (MZ). mDA 
progenitors are in the VZ and express Sox2, Lmx1a/b. mDA 
precursors or neuroblasts are in IZ and express Lmx1a/b, 
Nurrr1. Mature mDA neurons can be found in MZ and 
express Pitx3, Th. Aq: Aqueduct. 
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al., 1998; Wassarman et al., 1997). At the end of gastrulation (E7.5 in mouse), the transcription 
factors, Otx2 in the midbrain and Gbx2 in the hindbrain, are expressed in a complementary 
pattern, to drive the formation of IsO in MHB (Broccoli et al., 1999; Millet et al., 1999; 
Wassarman et al., 1997). This center produces WNT1 in the midbrain side and FGF8 in the 
hindbrain side. During these and subsequent developmental stages, the combined action of 
transcription factors and morphogens from the IsO orchestrate multiple functions. These 
include providing regional identity of the VM, controlling the specification and proliferation 
of mDA progenitors, mDA neurogenesis, as well as the promoting the differentiation and 
survival of mDA neurons (Arenas et al., 2015; Dworkin and Jane, 2013). 
1.4.2 Specification and differentiation of midbrain dopaminergic neurons 
SHH, a morphogen initially secreted by the notochord at E8 and expressed in FP by E8.5 in 
mice, induces the expression of Foxa2 in the FP (Ang et al., 1993; Sasaki et al., 1997). Foxa2 
plays a central role downstream of SHH as it is required for notochord and FP development as 
well as for ventral patterning (Ang et al., 1994; Weinstein et al., 1994). By contrast, in the BP, 
lower levels of SHH upregulate Nkx6-1 and Otx2. FOXA2 also induces Nkx6-1 in the BP 
(Nakatani et al., 2010) and suppresses Nkx2-2 in the FP (Ferri et al., 2007). Moreover, FOXA2 
directly represses Gli1-3 and upregulates Shh expression (Metzakopian et al., 2012).  
FOXA1/2 and OTX2 regulate the expression of two LIM homeobox transcription factors, 
Lmx1b and Lmx1a in mFP. Whereas Lmx1b is necessary for the differentiation of mDA 
progenitors (Smidt et al., 2000), Lmx1a is required for the specification of mDA neurons in the 
FP (Andersson et al., 2006a; Deng et al., 2011) and, via Msx1, suppresses the emergence of BP 
fates (Andersson et al., 2006a). Additionally, Otx2 sustains the expression Nkx6-1 in the BP 
and suppresses Nkx2-2 in the FP (Puelles et al., 2004). Thus, the concerted action of the Shh-
Foxa2 and the Otx2-Wnt1-Lmx1a/Msx1 networks is essential not only for the specification of 
the FP but also for the suppression of alternative neural fates. 
In the FP, Wnt1/β-catenin (Ctnnb), Lmx1a and Lmx1b form a positive autoregulatory loop 
(Chung et al., 2009) required for mDA specification: on the one hand β-catenin, together with 
TCF/LEF,  directly upregulates Lmx1a and Otx2, and, on the other hand, Lmx1a/b directly 
upregulate each other as well as Wnt1, Msx1 and two key genes involved in mDA neuronal 
differentiation and survival, Nurr1 (Nr4a2, nuclear receptor 4a2) and Pitx3 (Pituitary 
homeobox 3). Combined, these results indicate that the specification of mDA neurons is 
controlled by the Lmx1a/b-Wnt1/Ctnnb autoregulatory loop together with Otx1/2 and Foxa1/2.  
It has been recently shown that Foxa2 also interacts with components of the Wnt1-Lmx1a/b 
network. Indeed, FOXA2 directly promotes the expression of Lmx1a/b and Msx1 and 
upregulates the expression of Neurog2 (Metzakopian et al., 2012). Neurog2 is a basic-loop-
helix transcription factor required for mDA neurogenesis (Andersson et al., 2006b; Kele et al., 
2006b), whereas Ascl1 (Mash1, mouse achaete-schute homolog 1; another proneural gene of 
the basic-helix-loop-helix family) is capable of partially compensating for the loss of Neurog2 
(Kele et al., 2006b). These two proneural genes are directly or indirectly regulated by, and 
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integrate information from, the Shh-Foxa2 and Lmx1a/b-Wnt1-Otx2 networks (Arenas et al., 
2015), as well as from nuclear receptors of the Liver X receptor family (Lxrα/Nr1h3 and 
Lxrβ/Nr1h2) (Sacchetti et al., 2009) and the morphogen Wnt5a (Andersson et al., 2008), which 
also control mDA neurogenesis. 
1.4.3 MicroRNAs  
MicroRNAs (miRNAs) are short (about 22 nucleotides (nt)) non-coding RNA molecules, 
which are produced in three steps: (1) Primary miRNAs (pri-miRNAs) are transcribed by RNA 
polymerase II; (2) Drosha, a nuclear-localized RNA endonuclease III, cleaves the pri-miRNA 
duplex transcripts into ~70 nt stem loops called precursor mRNAs (pre-miRNAs); (3) The pre-
miRNAs are then exported to the cytoplasm where they are cleaved by the Dicer enzyme into 
~22 nt mature miRNA double-stranded duplexes (Winter et al., 2009). Such duplexes are 
loaded into miRNA-induced silencing complexes where only one strand is left to serve as a 
guide for imperfect base pairing with its target mRNAs. Nucleotides 2~7 in the 5’ terminus of 
the miRNA, called the “seed” sequence, are the most critical for recognition of the target 
mRNA (Pasquinelli, 2012). 
MiRNAs act thus as post-transcriptional regulators of gene expression (Bartel and Chen, 2004; 
Ebert and Sharp, 2012). This layer of regulation is important because miRNAs are found in 
most organisms and regulate around 60% of the predicted protein-coding genes (Grün et al., 
2005). The flexibility and reversibility of miRNA function enable a precise temporal and spatial 
gene regulation, which is crucial for the correct functioning of the nervous system (Davis et al., 
2015). Indeed, miRNAs control multiple stages of neuronal development (Davis et al., 2015; 
Petri et al., 2014). In agreement with this, conditional knockout of Dicer in postmitotic mDA 
neurons has been shown to result in progressive apoptosis of mDA neurons, leading to 
behavioral defects and alterations in locomotion (Kim et al., 2007). 
1.4.4 Wnt signaling 
Wnts are a large family of lipid-modified proteins formed by 19 members that bind to and 
activate a common signaling module formed by Frizzled (Fz) receptors (10 family members), 
and the intracellular signaling component, dishevelled (Dvl; 3 members). In addition, Wnts 
interact with different types of co-receptors, which recruit additional signaling components and 
transduce the Wnt signal in different ways (Niehrs, 2012).  
There are three main signaling pathways. The most well known and most well studied is the 
canonical or Wnt/Ctnnb1 signaling pathway. This pathway is activated by Wnts such as WNT1 
or WNT3A and uses the low-density lipoprotein receptor-related protein 5 or 6 (LRP5/6) as 
co-receptors. Upon activation, a destruction complex formed by adenomatous polyposis coli 
(APC), Axin, glycogen synthase kinase 3 (GSK3) and casein kinase 1 (CK1) is inhibited 
resulting in stabilization (lack of degradation) of CTNNB1, which then translocates to the 
nucleus and regulates, together with T cell factor (TCF) or lymphoid enhancer-binding factor 
(LEF), the transcription of Wnt target genes (Arenas, 2014). In the developing midbrain, this 
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pathway promotes key processes such as mDA neuron specification, proliferation and 
neurogenesis (Inestrosa and Arenas, 2010). 
The second most well-known pathway is the Wnt/planar cell polarity (PCP) pathway. This 
pathway is activated by WNT5A in the developing midbrain and uses the receptor tyrosine 
kinase-like orphan receptor 1/2 (ROR1/2). This receptor has been found to interact with core 
PCP signaling components such as Van Gogh-like 2 (VANGL2) to transmit the morphogenetic 
gradients established by WNTs (Gao et al., 2011). Upon activation, this pathway leads to the 
activation of small GTPases, such as RAC1, by guanine exchange factors, such as TIAM1 
(Čajánek et al., 2013). This pathway controls not only neural tube closure and morphogenesis, 
but also mDA neuron differentiation (Arenas, 2014). 
The third main pathway is the Wnt/calcium pathway, which activates calcium sensitive proteins 
such as protein kinase C (PKC), calcium-calmodulin-dependent kinase II (CamKII) or 
calcineurin and regulate the nuclear factor of activated T cells (NFAT) (Arenas 2014).  This 
pathway has not been linked to mDA neuron development, but can regulate processes such as 
proliferation and differentiation (Huang et al., 2011). 
 
1.5 MIGRATION OF POSTMITOTIC DOPAMINERGIC NEURONS 
1.5.1 Cell migration  
Cell migration is a widespread process in the developing central nervous system (CNS). This 
process allows neural cells to move away from their place of origin in the germinal zones and 
reach their final positions. The migratory behavior of newborn cortical neurons is by far the 
best well studied. Three modes of migration have been described in the cortex: somal 
translocation and radial locomotion (both perpendicular to the ventricular surface), and 
tangential locomotion (Nadarajah and Parnavelas, 2002). Cortical pyramidal neurons are 
generated in the germinal ventricular zone (VZ) and begin their migration as they leave the VZ 
to populate the primordial plexiform layers. Somal translocation is adopted by early generated 
neurons once the tip of their process attaches to the pia surface (Miyata et al., 2001; Nadarajah 
and Parnavelas, 2002). As corticogenesis proceeds, the cortex becomes thicker and neurons 
start radial glia-dependent locomotion. In this process, newborn neurons attach to radial glia 
processes and migrate away from the VZ, towards superficial destinations. Cortical 
interneurons, which originate in the ventral telencephalon, instead migrate tangentially and 
invade the cortical plane (Evsyukova et al., 2013; Marín et al., 2010; Nadarajah and Parnavelas, 
2002; Valiente and Marín, 2010). 
1.5.2 Cellular mechanisms in neuronal migration 
Locomotion is the standard way that neurons use for migration. At a cellular level, this process 
involves three steps: (1) extension of the leading process, to explore the immediate environment 
for attractive or repulsive cues; (2) movement of the nucleus into the leading process, also 
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called ‘nucleokinesis’; and (3) retraction of the trailing process/es (Evsyukova et al., 2013; 
Marín et al., 2010; Nadarajah and Parnavelas, 2002).  
Newly born cortical pyramidal neurons have a single process when they leave VZ, but they 
transiently assume multipolar morphology within the lower intermediate zone (IZ) and SVZ 
(Evsyukova et al., 2013; Marín et al., 2010; Noctor et al., 2001). Multipolar neurons possess 
multiple thin processes that extend and retract in a dynamic but apparently random fashion. 
Once they attach to radial glia processes they become bipolar again, with a long leading process 
and a short trailing process. Multipolar-bipolar transition is critical for radial glia-based 
migration and depends on the function of filamin A, Lissencephaly 1 (LIS1), doublecortin 
(DCX), fragile X mental retardation protein (FMRP) and Wnts (Boitard et al., 2015; La Fata et 
al., 2014; LoTurco and Bai, 2006). The leading process acts as the compass of migrating 
neurons, selecting the direction of migration in response to chemotactic cues. 
Nucleokinesis follows the extension of the leading process, following the direction of 
migration. Nucleokinesis is a subcellular process involving extensive and rapid cytoskeletal 
rearrangements of both microtubules and actin, which results in the translocation of the nucleus 
into the leading process. During nucleokinesis, the centrosome and its accompanying 
organelles move into the swelling formed by the base of the leading process, followed by the 
 
Figure 2.  Coordinated events required for somal movement during saltatory migration. (1) The 
growth cone in the tip of the leading process extends toward the direction of the intended migration. 
(2) A swelling (dilation) forms at the base of the leading process where it adheres to the matrix 
substrate. The centrosome (red) moves towards the dilation. (3-4) The nucleus translocates into the 
dilation. This process is called nucleokinesis. (5) The trailing process retracts and a new dilation 
forms to start a new cycle of the process. +/-: plus/minus ends of microtubules. Modified from Cooper 
(2013). 
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nucleus and the rest of the cell body (Figure 2) (Evsyukova et al., 2013; Valiente and Marín, 
2010).   
Extension of leading process and nucleokinesis are repeated to produce the typical saltatory 
movement of migrating neurons. When the leading process reaches the pial surface, migrating 
neurons detach form the radial glia process and move in a similarly way as during somal 
translocation to get to their final position. 
1.5.3 Molecular cues regulating neuronal migration 
A large numbers of secreted molecules and their membrane receptors have been shown to 
regulate neuronal migration, either chemoattractively or chemorepulsively. Most of those cues 
also regulate axon guidance (Evsyukova et al., 2013; Valiente and Marín, 2010), which also 
depend on the regulation of cytoskeletal elements such as microfilaments and microtubules 
(Dent et al., 2011; Evsyukova et al., 2013; Park et al., 2002; Valiente and Marín, 2010).  
Reelin is a secreted glycoprotein and one of the most well-studied guidance cue molecules. 
Reelin regulates both radial and tangential migration and its mutation causes layering and 
migration defects in multiple brain regions, from the cerebral cortex to the VM and the spinal 
cord (Katsuyama and Terashima, 2009; Lambert de Rouvroit and Goffinet, 2001; Rice and 
Curran, 1999; Vaswani and Blaess, 2016). Reelin signaling involves binding to the ApoER2 
and VLDLR receptors (Trommsdorff et al., 1998) and tyrosine phosphorylation of DAB1, 
which stabilizes microtubule through microtubule associated protein tau and MAP1B (Beffert, 
2004; González-Billault et al., 2005; Hiesberger et al., 1999).  
Another important signal is Slit, a secreted glycoprotein that binds to its cognate receptor 
ROBO (Roundabout), to induce repulsion and control neuronal tangential migration away from 
the midline (Wong et al., 2001; Ypsilanti et al., 2010). Binding of SLIT to ROBO increase the 
affinity of the intracellular CC3 motif of ROBO to SLIT-ROBO GTPase activation proteins 
(srGAPs) (Park et al., 2002; Wong et al., 2001). The srGAPs inactivate the small GTPases of 
the Rho family, mainly Cdc42 in SVZa cells, preventing it from activating an actin-nucleating 
factor, N-WASP, and thus abolishing actin polymerization associated with Arp2/3 protein 
activity and repelling cells from the slit-expressing SVZ region (Wong et al., 2001).  
1.5.4 Migration of mDA neurons 
When mDA precursors leave the VZ, they sequentially follow radial and tangential migration 
routes (Hanaway et al., 1971; Kawano et al., 1995). During radial migration mDA neurons 
attach to VIMENTIN+ radial glia fibers (Shults et al., 1990). After radial migration, when mDA 
neurons reach the marginal zone, mDA neurons destined to become SNc take a tangential 
pathway to migrate laterally and reach their final lateral destination. A panel of molecular cues 
have been reported to play a role in tangential migration of mDA neurons, such as neural L1 
cell adhesion molecule (L1CAM) (Demyanenko et al., 2001; Ohyama et al., 1998) and Reelin 
(RELN) (Bodea et al., 2014; Kang et al., 2010; Nishikawa et al., 2003; Sharaf et al., 2015). 
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Netrin/Dcc signaling has also been shown to not only regulate mDA positioning but also cell 
death and the dopaminergic innervation of the striatum and cortex (Xu et al., 2010). 
1.5.5  The CXCL12/CXCR4 signaling pathway 
Chemokines (chemotactic cytokines) constitute a family of small protein ligands that are 
classified into four major groups (referred to as C, CC, CXC and CX3C), based on the location 
and organization of their cysteine residues. The CXC members, also called α-chemokine 
subfamily, have a single amino acid residue between the first two conserved cysteine residues 
(Zlotnik and Yoshie, 2012). CXCL12 (also known as stromal cell-derived factor 1, SDF1) is a 
member of the -chemokine subfamily and, together with its cognate receptor, CXCR4, 
represent the best-known chemokine ligand/receptor pair.  
The CXCR4 receptor is a 
member of the G protein 
coupled receptors 
(GPCRs) family. 
Activation of this receptor 
by CXCL12 leads to 
activation of Gi family of 
proteins. Activated Gi 
inhibit adenylyl cyclase 
and activate the Src family 
of tyrosine kinases, while 
liberated G activate 
phospholipase C- (PLC-
) and phosphoinositde-3 
kinase (PI3K) (Figure 3) 
(Busillo and Benovic, 
2007).  
 
 
 
 
Chemokines and their receptors are best known for their involvement in inflammatory and 
immune responses. Besides these roles, chemokines are expressed by all major cell types in the 
central nervous system (CNS). A growing body of evidence shows that chemokines and their 
receptors mediate cellular communication in the CNS (Mélik-Parsadaniantz and Rostène, 
2008; Mithal et al., 2012; Zhu and Murakami, 2012). For example, projection neurons in the 
IZ/SVZ of the cortex express Cxcl12 (Stumm and Höllt, 2007; Tiveron et al., 2006), and 
 
Figure 3. Components of the CXCR4 signaling pathway regulating 
cell migration. CXCL12 binding to CXCR4 leads to the activation of 
Gi and liberation of Gβγ, which in turn activate phospholipase C-β 
(PLC-β) and phosphoinositide-3 kinase (PI3K), ultimately leading to 
the regulation of cell migration. Activated CXCR4 also recruits 
JAK/STAT and activates this pathway. CXCR4 is phosphorylated 
after its activation. Figure modified from Busillo and Benovic (2007). 
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regulate the tangential migration of CXCR4-expressing GABAergic interneurons generated in 
the ventral forebrain (López-Bendito et al., 2008; Tiveron et al., 2006). In addition, Cxcl12 is 
persistently expressed in the leptomeninges (Paredes et al., 2006; Stumm et al., 2007), where 
it also regulates the tangential migration of GABAergic interneurons (López-Bendito et al., 
2008) and hem-derived Cajal-Retzius cells throughout the MZ of the cortex (Borrell and Marín, 
2006; Paredes et al., 2006). CXCL12/CXCR4 signaling is also responsible for the migration, 
assembly and positioning of cerebellar granule and Purkinje neurons (Ma et al., 1998), 
olfactory neurons (Miyasaka et al., 2007), as well as facial motoneurons (Sapède et al., 2005). 
Moreover, CXCL12/CXCR4 signaling is required for guiding the initial trajectory of ventral 
motoneurons (Lieberam et al., 2005) and for axon pathfinding of retinal ganglion cells and 
olfactory neurons (Li et al., 2005; Miyasaka et al., 2007). Similarly, the migration and final 
position of trigeminal and dorsal root ganglion cells, as well as their target innervation also 
require CXCL12/CXCR4 (Balabanian et al., 2005; Knaut et al., 2005; Odemis et al., 2005). 
Thus, CXCL12/CXCR4 signaling regulates the three key processes essential for the 
establishment of neural networks in different neuronal systems: neuronal migration, cell 
positioning and axon wiring. 
1.5.6 Coordination of neurogenesis and migration 
As mentioned above, postmitotic neurons start to migrate immediately after neurogenesis. 
Several lines of evidence indicate that neurogenesis and migration are coupled. Some of the 
most important genes regulating neurogenesis are basic helix-loop-helix (bHLH) genes, such 
as Neurog1/2 and Ascl1, which initiate a cascade of bHLH gene activation events that 
eventually lead to the expression of terminal neuronal differentiation genes in central nervous 
system (Andersson et al., 2006b; Bertrand et al., 2002; Kele et al., 2006a; Ma et al., 1997). 
Once a progenitor is committed to neuronal fate by expressing proneural genes, Scrath1/2, an 
epithelial-mesenchymal transition (EMT) factor, is induced to initiate the migratory process 
(Itoh et al., 2013). Proneural bHLH factors down-regulate the RhoA small GTPase and up-
regulate DCX and p35 expression, which modulate the actin and microtubule cytoskeleton 
assembly and enable newly generated neurons to migrate (Ge et al., 2006). Further analysis has 
shown that NEUROG2 induces the expression of small GTP-binding protein, Rnd2, to 
antagonize the activity of RhoA and promote multipolar-bipolar transition in the cortical IZ 
(Heng et al., 2008). Similarly, ASCL1 induce Rnd3 to inhibit RhoA activity via the Rho 
GTPase activating protein, p190RhoGap, in order to promote locomotion in the cortical plate 
(Pacary et al., 2011).  
 
1.6 DIFFERENTIATION OF MIDBRAIN DOPAMINERGIC NEURONS 
During migration from the IZ to the MZ, postmitotic precursors continue their differentiation, 
becoming mature mDA neurons. Early factors controlling mDA neurogenesis, such as Otx2, 
Lmx1a/b, Foxa1/2 and En1/2, remain expressed and up-regulate later factors, such as 
Nurr1/Nr4a2 and Pitx3. Nurr1 is required for mDA neuroblast survival and differentiation into 
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TH+ mDA neurons (Zetterström et al., 1997). Accordingly, Nurr1/Nr4a2 has been found to 
regulate the expression of several genes that define a mature mDA neuron, including Th, 
Slc18a2/Vmat2 (solute carrier family-18 member-2/vesicular monoamine transporter-2), 
Slc6a3/Dat (solute carrier family-6 member-3/dopamine transporter), Ddc/Aadc, and Cdkn1c 
(cyclin-dependent kinase inhibitor 1C) (Gil et al., 2007; Jankovic et al., 2005; Joseph et al., 
2003; Saucedo-Cardenas et al., 1998; Smits et al., 2003; Wallen et al., 2001; Volpicelli et al., 
2007; Zetterströmetal.,1997). In addition, Pitx3 directly regulates the Aldh1a1 gene (aldehyde 
dehydrogenase-1a1), an enzyme in the synthesis of retinoid acid (Jacobs et al., 2007), which in 
turn regulate Th, Dlk1 (Delta-like 1) and D2R (Jacobs et al., 2011). Moreover, PITX3 
cooperates with NURR1 to activate transcription of Aadc (aromatic L-amino acid 
decarboxylase), D2R, Dat and Vmat2 (Hwang et al., 2009; Jacobs et al., 2009). LMX1A/B 
directly regulates Nurr1 and Pitx3 (Chung et al., 2009). Moreover, FOXA1/2 are required for 
the expression of Nurr1, En1 and Aadc in mDA neuroblasts and neurons, as well as for the 
expression of Th in mDA neurons (Ferri et al., 2007; Metzakopian et al., 2015; Stott et al., 
2013).  
1.7 SURVIVAL OF MIDBRAIN DOPAMINERGIC NEURONS 
Understanding the factors that control the survival of mDA neurons, especially SNc neurons, 
has been an intense topic of research in the field. Genetic studies have shown transcription 
factors involved in the terminal differentiation of mDA neurons are also important for neuronal 
survival. Nurr1 regulates the expression of Brain-derived neurotrophic factor (Bdnf) and the 
glial cell-line derived neurotrophic factor (GDNF) receptor, c-ret (Barneda-Zahonero et al., 
2012; Wallén A et al., 2001). Moreover, PITX3 has been found to be required for GDNF-
induced Bdnf expression in SNc mDA neurons (Peng et al., 2011). These neurotrophic factors, 
BDNF (Barde et al., 1982; Leibrock et al., 1989) and GDNF (Lin et al., 1993) are the two most 
commonly used factors to maintain the survival and promote the differentiation of mDA 
neurons in stem cell biology. BDNF is known to promote the survival of fetal mDA neurons 
in primary cultures and to protect mDA neurons against neurotoxins both in vitro (Hyman et 
al., 1991) and in vivo (Frim et al., 1994). Similarly, GDNF was found to promote the survival 
and differentiation of mDA neurons in vitro (Lin et al., 1993) and to prevent their loss in animal 
models of PD (Beck et al., 1995; Tomac et al., 1995). Multiple other neurotrophic factors are 
currently known to promote the survival and/or differentiation of mDA neurons and have been 
suggested as therapeutic tools for PD (for review see Aron and Klein, 2011; Lindholm et al., 
2016). 
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2 RESULTS AND DISCUSSION 
2.1 Paper I 
In this paper, we investigated whether the Wnt/β-catenin and Wnt/PCP signaling need to be in 
balance during mDA neuron development. Wnts are a family of secreted proteins that regulate 
multiple steps of neural development and stem cell differentiation. Two of them, Wnt1 and 
Wnt5a, activate distinct branches of Wnt signaling and individually regulate different aspects 
of mDA neuron development. However, several of their functions and interactions remain to 
be elucidated. Here we analyzed mDA neurogenesis in Wnt1-/- single and Wnt1-/-;Wnt5a-/- 
compound knockout mice and developing an improved protocol for the differentiation of 
mouse ES cells into mDA neurons.  
First, we found that Wnt1 is required for mDA neurogenesis. Analysis of the Wnt1-/- mice 
revealed that the expression patterns of Shh and Foxa2 were delayed, phenocopying the β-
catenin-/- mice (Joksimovic et al., 2009). Moreover, Lmx1a, was found to be absent from the 
FP of Wnt1-/- mice at E11.5. Previous in vitro experiments have indicated that β-catenin 
regulates Lmx1a via an auto-regulatory loop (Chung et al., 2009) and that deletion of β-catenin 
results in ectopic expression of Lmx1a in vivo (Tang et al., 2009). Because Wnt1 activates 
Wnt/β-catenin signaling, our results indicate that it is Wnt1 that regulates the levels and position 
of Lmx1a in vivo. Interesting, Lmx1a was ectopically expressed in the BP of Wnt1-/- mice at 
E11.5, but the expression of other FP and BP markers, such as Shh and Nkx6-1, was conserved, 
indicating FP and BP patterning is not altered. 
Then we asked whether general neurogenesis is affected in Wnt1-/- mice and examined the 
expression of two critical proneural transcription factors, Neurog2 and Mash1, in the VM of 
Wnt1-/- mice at E11.5. We found that both Neurog2 and Mash1 were completely absent in the 
mFP, but Neurog2 was expressed in the BP of Wnt1-/- mice at E11.5. In line with this, staining 
for TUJ1, a postmitotic pan-neuronal maker, and Topro3, a DNA dye to show nuclei, revealed 
no TUJ+/Topro+ cell bodies in the FP, indicating that the FP region of Wnt1-/- mice contains no 
newborn neurons. Moreover, no NURR1+ mDA neuroblasts were detected in the FP. In fact, 
the only cell bodies found in the FP of Wnt1-/- mice were those of SOX2+ ventricular zone 
neuroepithelial cells and GLAST+ radial glia. Notably, a reduced number of NURR1+/TH- 
mDA neuroblasts and TH+ mDA neurons were found in an ectopic lateral position in the BP. 
Thus, our results indicate that Wnt1 is required not only for the expression of Lmx1a and 
proneural genes (Mash1 and Ngn2) in the midbrain FP but also for mDA specification and 
neurogenesis. 
We then examined mDA neurogenesis in Wnt1-/-;Wnt5a-/- compound knockout mice. The 
phenotype of these mice resembled the combination of the two single phenotypes and showed 
exacerbated caudal phenotypes, a shortened and truncated midbrain, and a flattening of the FP 
region. Previous studies have indicated that deletion of Wnt1 reduces (Prakash et al., 2006) but 
deletion of Wnt5a increases (Andersson et al., 2008) progenitor proliferation in the midbrain 
FP. Although no difference in phospho-histone 3 (PH3) staining (for cells in M-phase) was 
 14 
detected in the BP of Wnt1−/− or Wnt1−/−;Wnt5a−/− mice, significant and specific changes were 
detected in the FP. Indeed, deletion of Wnt5a in Wnt1−/− mice rescued the loss of PH3+ cells in 
the FP. Moreover, Wnt5a served a stronger anti-proliferative role in the absence of endogenous 
Wnt1. Thus, our results indicate that Wnt1 and Wnt5a interact in an antagonistic manner to 
regulate proliferation in vivo. Surprisingly, the partial rescue of progenitor proliferation by 
deletion of Wnt5a in Wnt1−/−;Wnt5a−/− mice didn’t lead to an increase of the number of Nurr1+ 
postmitotic precursors, but rather a further decrease in Nurr1+ cells from 57% in Wnt1−/− mice 
to 81% in Wnt1−/−;Wnt5a−/− mice. Moreover, TH+ mDA neurons were nearly completely 
absent in VM of Wnt1−/−;Wnt5a−/− mice at E12.5. These results indicated that Wnt1 and Wnt5a 
cooperate in the generation of postmitotic cells as well as in the maturation of mDA precursors.  
Analysis of morphogenesis in compound Wnt1−/−;Wnt5a−/− mutants showed a Wnt5a−/−-like 
phenotype, with a severe broadening of the ventricular cavity and flattening of the VM hinge 
point, while Wnt1 single knockout leads to an elongation of the ventricular cavity and of the 
VM hinge point. Moreover, we found that the A-P distribution of the TH+ mDA domain, was 
further shortened from 55% in Wnt1−/− mice, to 85% in Wnt1−/−;Wnt5a−/− mice. Additionally, 
TH+ cells occupied more lateral and dorsal positions in the Wnt1−/−;Wnt5a−/− mice than in 
either of the single mutants. Thus, our results show that an unsuspected cooperation between 
Wnt1 and Wnt5a regulate VM morphogenesis in vivo.  
These results indicate the existence of a broad cooperation of the Wnt/β-catenin and Wnt/PCP 
signaling pathways, which could be mediated by shared signaling components of the two 
pathways, such as Fz or Dvl. Indeed, we and others have reported previously that signaling 
components initially assigned to the Wnt/β-catenin pathway, such as the Lrp6 co-receptor, can 
contribute to convergent extension and Wnt/PCP signaling (Bryja et al., 2009; Tahinci et al., 
2007). Thus, multiple mechanisms could account for the interaction between these two 
pathways. 
We next examined whether activation of Wnt/β-catenin and Wnt/PCP signaling could be used 
to improve protocols for the differentiation of mouse neural and ES cells into mDA neurons. 
Because there is no commercially available active WNT1 protein (capable of activating the 
very sensitive Wnt/β-catenin reporter, TOPFLASH), we used WNT3A to activate Wnt/β-
catenin signaling. We first examined neural stem cells and administered WNT3A for 3 days, 
to promote progenitor proliferation and specification, followed by 3 days without WNTs, and 
finally 3 days with WNT5A, to activate the Wnt/PCP/Rac1 pathway and promote progenitor 
cell-cycle exit, neurogenesis and NURR1+ precursor differentiation into TH+ DA neurons. 
Sequential administration of WNT3A and WNT5A increased the proportion of DA neurons 
per TUJ1-stained area by 2.5-fold compared with WNT3A, while WNT5A showed a small 
increase. This protocol was then adapted to mES cell cultures by shortening from 3 to 2 days 
each of the three steps (Wnt3a/no Wnt/Wnt5a) (Figure 4). These three steps were performed 
between days 7–13, after the neural-induction with Noggin (days 1–5) and the beginning of 
Fgf8/Shh-patterning (days 5–7) which continued until day 13. A final standard differentiation 
step with survival/differentiation factors such as BDNF and GDNF was included to enhance 
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the maturation of DA neurons on days 13–15/16. As observed with neural stem cells, treatment 
of mES cells with WNT3A had no effect on the number of TH+ cells in the cultures. Sequential 
administration of Wnt3a followed by WNT5A led to a very significant (60%) increase in the 
percentage of TH+ cells compared with control or Wnt3a alone. Additionally, sequential 
WNT3A and WNT5A treatment also increased by 80% the proportion of TUJ1+ neurons that 
became TH+. Finally, sequential Wnt treatment increased the proportion of TH+ cells 
expressing Foxa2 by 55%, Lmx1a by 29%, Pitx3 by 31%, and Nurr1 by 14%. Thus, our results 
indicate that, by improving our understanding of the basic mechanisms by which Wnts operate 
during normal midbrain development, it is possible to improve current protocols for the mDA 
differentiation of neural or ES cells. 
 
2.2 Paper II 
In this paper, we investigated whether and how CXCL12/CXCR4 signaling is involved in 
migration and neuritogenesis of mDA neurons.  
We first examined the expression of the chemokine Cxcl12 and its receptor Cxcr4 in 
developing VM in mice. In situ hybridization showed that Cxcl12 is present in the meninges 
surrounding the VM during mDA neurogenesis and Cxcr4 is expressed in the precursor 
domain, marked by Nr4a2/Nurr1. Immunostaining of CXCR4 and NURR1 confirmed that two 
proteins are co-localized in mDA precursors. The CXCR4 antibody (UMB-2) used in 
immunostaining is only able to recognize naive CXCR4 which has not been activated by 
phosphorylation (Sánchez-Alcañiz et al., 2011). Staining of CXCR4 in tissue sections pre-
treated with protein phosphatase revealed the presence of additional signal corresponding to 
phosphorylated CXCR4. Comparison of consecutive sections with or without protein 
phosphatase treatment, revealed that phosphorylated active CXCR4 is present in both mDA 
precursors (NURR1+TH-) and TH+ mDA neurons. This was also confirmed by immunostaining 
with antibodies against phosphorylated S324/325 and S338/339 of CXCR4. Notably, the 
 
Figure 4. Scheme showing the protocol for mouse ES cells differentiation into dopaminergic neurons 
by incorporating sequential WNT3A and WNT5A treatment. From paper I (Andersson et al., 2013). 
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UMB-2 antibody recognizes non-phosphorylated S346/347 in human CXCR4, which is the 
main site for functional regulation of CXCR4 as it is required for subsequent phosphorylation 
of S324 and S338/339 (Mueller et al., 2013). These results revealed that CXCR4 begins its 
activation in NURR1+/TH- precursors of the IZ and is fully activated in most NURR1+/TH+ 
mDA neurons of the MZ by E12.5, as they move closer to the meninges.  
We then analyzed the function of meningeal CXCL12 on CXCR4+ mDA neurons in vitro. First 
we did midbrain organotypic slice cultures. In slices where meninges were removed, more TH+ 
cells were found in ectopic lateral positions in the IZ, compared with slices with intact 
meninges. The width of bundles containing TH+ processes increased in slices without 
meninges. Importantly, CXCR4 immunoreactivity (UMB-2 antibody) was also higher without 
meninges, indicating less activation of the receptor. Migration assays were also performed to 
test whether the meninges are capable of promoting the migration of mDA neurons in a 
CXCR4-dependent way. Meninges were dissected out and when placed next to a piece of VM 
tissue, they induced the migration of TH+ cells towards them and promoted neuritogenesis in 
TH+ cells. Both effects were blocked by a CXCR4 antagonist AMD3100. These results clearly 
show that CXCL12/CXCR4 signaling may regulate mDA neuron migration and 
neuritogenesis. 
To confirm these results we examined whether CXCL12/CXCR4 signaling is involved in mDA 
neuron migration in vivo and performed first gain of function experiments. When CXCL12 was 
overexpressed ectopically, lateral to the FP, TH+ cells migrated towards Cxcl12-expressing 
GFP+ cells. In agreement with the hypothesis that CXCR4+ cells migrate along a CXCL12 
gradient, when this gradient was disturbed by Cxcl12 overexpression in the medial floor plate, 
TH+ cells were retained in the IZ. Then we performed loss of function experiments and 
examined the phenotypes of mDA neurons when CXCR4 was either pharmacologically 
blocked by AMD3100 or genetically deleted in Cxcr4 knockouts. At E11.5, TH+ cells in Cxcr4-
/- were retained in IZ and their processes were disoriented (not radially oriented as in wild type). 
The retention of TH+ cells in the IZ was also found at later stages, in either Cxcr4-/- mice or in 
mice intraventricularly injected with AMD3100. We also found that the neurites of TH+ cells 
reaching the lateral part of the MZ were more oriented towards the meninges in control Cxcr4+/- 
mice than in Cxcr4-/- embryos, a finding consistent with the fasciculation defects found in 
organotypic cultures without meninges.  
In this paper, we thus identify that the CXCL12/CXCR4 signaling pathway controls mDA 
migration and neuritogenesis (Figure 5). CXCL12/CXCR4 has been shown to regulate the 
migration of multiple types of immature neurons and serve different purposes in different brain 
regions (see introduction). For instance, while meningeal CXCL12 serves as an anchoring 
factor to retain proliferating cerebellar precursors in the external granule layer (Reiss et al., 
2002; Zhu et al., 2002) and in the dentate gyrus of hippocampus (Li et al., 2009), it works as 
chemoattractant to stimulate the migration of hem-derived Cajal-Retzius cells in the cerebral 
cortex (Borrell and Marín, 2006). In the developing midbrain, it has been known mDA 
neuroblasts migrate first ventrally and then tangentially towards their lateral destination 
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(Hanaway et al., 1971; Kawano et al., 1995). However little was known about the molecular 
players in the process, especially for radial migration. Here, we show that CXCL12/CXCR4 
plays an important role in radial migration. In addition we found that that CXCL12/CXCR4 
regulates neurite growth, a finding that is supported by previous studies showing that migration 
cues also regulate axon pathfinding (Marín et al., 2010; Ward and Rao, 2005). Finally, from an 
applicative point of view, we speculate that CXCL12 may be used in cell replacement therapies 
for PD, to improve neuroblast migration out of the graft and dopaminergic innervation of the 
host striatum, both of which may contribute to better functional integration of transplanted 
mDA neurons. 
 
2.3 Paper III 
In this paper, we investigated how the homeodomain transcription factor, ZEB2, regulates 
mDA neurogenesis and migration. 
First, we examined the expression of Zeb2 in the VM during development. In situ hybridization 
showed that Zeb2 is expressed in the VZ of the FP and BP, as well as in the IZ. 
Immunofluorescence confirmed the presence of ZEB2 in SOX2+ VZ cells. The expression 
levels of ZEB2 in the IZ were much lower lever than in the VZ, and they were complementary 
to the levels of NR4A2/CXCR4, suggesting that ZEB2 is being downregulated in postmitotic 
mDA neuroblasts while they start migrating.  
We then set out to investigate what are the target genes of ZEB2, and examined the DNA 
sequences bound by this transcription factor. For this purpose, we took the advantage of the 
ChiP-seq dataset from the ENCODE project. Analysis of the transcription factor binding-site 
motifs showed that ZEB2 and ZEB1 bind nearly identical sequences. Accordingly, these two 
proteins are known to serve similar functions (Bracken et al., 2008; Cong et al., 2013; Ellis et 
al., 2010; Park et al., 2008). ZEB transcription factors were found to interact with the promoter 
 
Figure 5. Migration of postmitotic DA neurons. Postmitotic DA neuroblasts (blue) migrate radially along the 
radial glia processes, from the IZ (intermediate zone) to MZ (marginal zone), following the gradient of 
CXCL12 secreted by the meninges (orange). VZ, ventricular zone. Modified from paper II (Yang et al., 2013). 
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of genes known to regulate mDA development, such as NEUROG2, NR4A2, CXCR4 and 
PITX3. Moreover, overexpression of Zeb2 in the substantia nigra dopaminergic cell line, 
SN4741, led to a down-regulation of Cxcr4 mRNA, indicating that ZEB2 works as a 
transcription repressor.  
To examine the function of ZEB2 in vivo, we overexpressed Zeb2 in the midbrain FP by in 
utero electroporation. We found that CXCR4 and NR4A2 (NURR1) immunoreactivity was 
lower in Zeb2 overexpressing cells compared with Gfp cells, indicating that ZEB2 represses 
the expression of these two ZEB2 target genes. As expected, down-regulation of CXCR4 in 
migratory mDA precursors reduced their migration and impaired their multipolar-to-bipolar 
transition, which is required for migration.  
Zeb2 has also been reported to represses the expression of miR-200 family members in cancer 
cells (Bracken et al., 2008). The miR-200 family is present in the VZ of the developing 
midbrain (Peng et al., 2012). We found that primary miR-200c (pri-miR-200c) is expressed in 
the VZ, as assessed by ISH, confirming the previous report. Moreover, we found that pri-miR-
200c is also expressed in the IZ of the FP, in CXCR4+ cells where ZEB2 immunoreactivity is 
much lower than that in the VZ. Interestingly, overexpression of ZEB2 up-regulated pri-miR-
200c at E12.5, 1 day after electroporation; and conversely, overexpression of pMiR-200c down-
regulated ZEB2 immunoreactivity in the FP in vivo. These results suggested a negative 
feedback loop formed by ZEB2 and miR-200c in the VM.  
Finally we examined the function of ZEB2-miR-200c loop in mDA neuron development by 
overexpressing a miR-200 sponge vector (pCAG-Sponge) to inhibit members of the miR-200 
family (Peng et al., 2012). We found that ZEB2 immunoreactivity was elevated when miR-
200s were knocked-down by overexpression of pCAG-Sponge in primary VM cell cultures. 
Overexpression of pCAG-Sponge resulted in the reduced migration and less NR4A2+/GFP+ out 
of the total GFP+ cells. These results indicated that a ZEB2-miR-200c loop controls the 
neuronal migration and differentiation of mDA neurons. 
In this study we thus describe a new regulatory loop involving the transcription factor ZEB2 
and the microRNA miR-200c in developing VM that controls the differentiation and migration 
of mDA neurons. The unilateral negative feedback nature of the loop indicates that the level of 
ZEB2 protein is critical for its function during FP development. These two factors, ZEB2 and 
miR-200c, seem to reach a balance as indicated by their co-expression in progenitor cells in 
VZ, while in the IZ, ZEB2 protein diminished in spite of the presence of both Zeb2 mRNA, 
indicating an ongoing inhibition by miR-200c. We thus suggest that ZEB2 may function to 
prevent premature mDA differentiation by repressing genes, such as Neurog2, Nr4a2, Cxcr4 
and Pitx3 in progenitors. Interestingly, we show here that ZEB2 promotes the expression of 
miR-200c, which is not the case in other cell types (Bracken et al., 2008; Park et al., 2008), 
reflecting the fact that ZEB2 can act as a transcriptional repressor or activator, depending on 
co-factor recruitment (Sánchez-Tilló et al., 2011). Notably, members of the miR-200 family 
can target a large number of proteins, two of which, SOX2 and E2F3 have been shown to 
regulate cell cycle exit in midbrain progenitors during neurogenesis (Peng et al., 2012). We 
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thus conclude that a complex regulatory network involving microRNAs of the miR-200 family 
and ZEB2 regulates not only mDA migration, but also neurogenesis.  
 
2.4 Paper IV 
In this paper, we investigated the impact of the extracellular matrix (ECM) on mDA neuron 
development in mouse embryos and in human long-term neuroepithelial stem (lt-NES) cells in 
culture. 
We first examined the composition of the ECM in the midbrain FP by RNA-sequencing. We 
focused on laminins, which are trimeric proteins consisting of and subchains (Lama, 
Lamb and Lamc, respectively). Analysis of the mouse VM tissue revealed that Laminin 
subchains Lama1, 4 and 5, Lamb1 and 2, and Lamc1 are abundant in the VM at E12.5. 
Interestingly, Lama5 was differentially expressed compared to the dorsal midbrain or ventral 
diencephalon or hindbrain. LAMA5 was detected in VM by immunofluorescence at E10.5 and 
E12.5 and was found to increase from low levels in the VZ to high levels in the MZ.  
Our sequencing data suggested that six possible trimeric laminins can be formed in the VM. 
Five of them (LM111, LM411, LM421, LM511, LM521) are currently available as protein and 
were used to test their functionality in primary mDA cultures. LM511 increased the percentage 
of LMX1A+ and TH+ cells, while LM211 and LM332 decreased that compared to LM111. 
Notably, LM521, which contains only a different  chain compared with LM511 (2 instead 
of 1), did not support mDA cells as LM511 did, indicating a highly specific role of the  
laminin chain. Indeed, LM511 reduced cell death in primary mDA neurons with or without 
oxidative stress challenge (induced by 6-hydroxydopamine). We also found that LM511 
represses the level of phosphatase and tensin homolog (PTEN) in the substantia nigra 
dopaminergic cell line, SN4741. PTEN, which is present in the developing VM, has been 
previously shown to antagonize PI3K activity and promote mDA neuron death (Stiles et al., 
2004). Moreover, we also found that LM511, but no other laminin, was able to upregulate YAP 
signaling in mDA neurons. YAP is a key transcriptional co-activator involved in the 
transduction of extracellular mechanical information (Dupont et al., 2011) as well as 
proliferation, differentiation and survival (Pan, 2010), but has not been linked to mDA neuron 
development.  
In order to dissect out the pathway by which LM511 may regulate YAP and PTEN, we first 
looked for the receptor mediating LM511 signaling. We thus performed a screen with blocking 
antibodies against the laminin receptors, integrins, and used YAP target genes CTGF and 
ANKRD1 as a readout. We found that Integrin 3 (ITGA3) blocking antibodies partially 
decreased the transcription of YAP target genes. Moreover, knock-down of Integrin 3, but 
not Integrin 6 (another receptor for LM511) (Hynes, 2002), induced YAP phosphorylation 
and upregulated PTEN levels. Interestingly, RNA-seq analysis showed Itga3 and Itgb1 are the 
two most abundant integrin transcripts in developing VM. Since Integrin α3β1 (ITGA3B1) is 
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the only 3 containing integrin among the 24 integrin heterodimers (Hynes, 2002), we 
conclude that ITGA3B1 mediates LM511-YAP signaling in mDA neurons.  
Immunostaining revealed that YAP is expressed in TH+ cells in the midbrain FP. We then set 
out to examine the function of YAP in mDA neurons. First, Yap overexpression was found to 
downregulate PTEN levels and knockdown of YAP increased PTEN levels in SN4741 cells. 
As expected from the pro-apoptotic role of PTEN, we found that Yap knockdown increased 
and overexpression reduced cell death and active Caspase 3 immunoreactivity in primary mDA 
neurons treated with the neurotoxin 6-hydroxydopamine, compared to shRNA control. The 
importance of YAP in mDA survival was confirmed in vivo by in utero electroporation of Yap-
shRNA in the midbrain FP, where more active Caspase 3+ cells were found compared with 
control. These results strongly indicate that YAP is required for mDA neuron survival in vitro 
and in vivo. We next sought to identify the factors mediating the effects of YAP and the 
inhibition of PTEN. Analysis of microRNA binding sites in the regulatory regions of Pten 
revealed several potential candidates. Of them, miR-130a and miR-107 were enriched in the 
midbrain tissue, but only miR-130a was up-regulated by LM511. Moreover, overexpression or 
knockdown of Yap respectively increased or decreased miR130a expression in SN4741 cells. 
Furthermore, LM511 induced the expression of miR130a, an effect that was partially blocked 
by Yap knockdown. Finally, overexpression of miR130a in the midbrain FP at E13.5, by in 
utero electroporation, knocked-down PTEN. Thus, our data show that LM511 up-regulates 
miR-130a via YAP, which in turn reduces the levels of PTEN in dopaminergic cells. 
In addition to the pro-survival role of YAP in mDA neurons, we also examined whether YAP 
promotes mDA neuron differentiation. We then overexpressed Yap in human lt-NES cells 
(Falk et al., 2012; Koch et al., 2009), which were subsequently differentiated towards mDA 
neurons. A set of mDA differentiation specific genes, such as LMX1A, LMX1B and PITX3, 
were up-regulated by Yap overexpression, compared with Gfp overexpression. Moreover, 
immunostaining revealed that LMX1A, LMX1B, PITX3, Aldehyde dehydrogenase1A1 
(ALDH1A1) and dopamine transporter (SLC6A3) proteins were increased in TH+ neurons 
derived from Yap-lt-NES cells compared to Gfp-lt-NES cells. Finally, overexpression of YAP 
in the developing VM also induced ectopic expression of PITX3, without affecting 
proliferation, suggesting an additional pro-differentiation effect of YAP.  
In this study we identify a novel pathway activated by LM511 in the ECM that controls mDA 
neuron survival and differentiation (Figure 6). Previous studies have identified that G protein-
coupled receptors (Yu et al., 2012; Zhou et al., 2014) and integrins (Elbediwy et al., 2016; 
Martin et al., 2016; Wong et al., 2016) transduce signals from the ECM to the cells via YAP 
signaling.  However, the molecular identity of the ECM signals remained unknown. Our study 
identifies LM511 as the first molecular entity in the ECM capable of activating YAP. Notably, 
YAP signaling is low in the brain because of the low stiffness of the tissue and the abundance 
of cell-to-cell contacts (Dupont et al., 2011; Varelas et al., 2012; Zhao et al., 2007). Our results 
suggest that the presence of LM511 in restricted sites of the ECM, such as the VM FP, may 
thus provide a mechanism to active YAP and regulate the survival and differentiation of 
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specific cell types such as mDA neurons. These novel functions of YAP, combined with its 
canonical role in transducing ECM stiffness (Dupont et al., 2011), indicate that the LM511-
YAP pathway may serve as an integrator of diverse ECM properties and as a coordinator of 
cellular responses to niche-derived signals.    
Multiple questions arise from 
these results, such as: How is 
the LM511 signal transduced 
from ITGA3B1 to YAP? Or 
what is the identity of the 
transcription factors 
interacting with YAP and 
contributing to provide cell 
type specificity in mDA 
neurons? Or what are the 
target genes of YAP in mDA 
neurons other than the ones 
identified here?  
  
 
 
 
From an applicative point of view, LM511 may be used to improve in vitro differentiation of 
mDA neurons derived from various types of stem cells.  In the future it will be also interesting 
to investigate whether and how the ECM plays role in the pathogenesis of Parkinson’s disease, 
since some evidence indicates that ECM degradation and alteration of ECM enzymes takes 
place in PD (Lorenzl et al., 2002; Yang et al., 2015).  
 
 
Figure 6. Schematic figure showing that the LM511-
ITGA3B1-YAP axis enhances mDA neuron survival via 
suppression of PTEN by miR-130a and promotes mDA neuron 
differentiation via up-regulation of mDA neuron transcription 
factors such as Lmx1a/b and Pitx3. From paper IV 
(manuscript). 
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3 CONCLUSIONS 
 
In this thesis, I present four projects, covering diverse aspects of midbrain development such 
as the specification, neurogenesis, migration, differentiation and survival of mDA neurons.  
The main conclusions of our studies are the following: 
1 Wnt1 and Wnt5a genetically interact and cooperate to control multiple aspects of mDA 
neuron development.  
2 Sequential application of Wnt3a and Wnt5a improves the mDA neuron differentiation of 
mouse ES Cells . 
3 CXCL12/CXCR4 regulates the radial migration and neuritogenesis of mDA neurons 
during development both in vitro and in vivo. 
4 ZEB2 activates the expression of miR-200c, which in turn represses Zeb2 expression, 
forming a unilateral negative feedback loop in VM floor-plate progenitors. 
5 ZEB2 represses the expression of Cxcr4 and Nr4a2 (Nurr1), to prevent premature 
migration and differentiation of mDA progenitors. 
6 LM511 activate YAP pathway throug Intergrin 31 in mDA neurons. 
7 LM511-YAP promotes the differentiation of mDA neurons. 
8 LM511-YAP induces miR-130a, which represses PTEN, resulting in increased survival 
of mDA neurons. 
The incorporation of the knowledge from developmental biology to regenerative medicine, 
particularly to improve the differentiation of pluripotent cells into mDA neurons, has been 
proven to be a successful strategy and I think it can further contribute in the future. The 
results we obtained from the four projects in my thesis have expanded our understating of 
mDA specification, neurogenesis, migration, differentiation and survival. My hope is that 
these studies will also contribute to the future development of novel therapeutic strategies for 
PD, such as cell replacement or neuroprotective therapies. 
  25 
4 ACKNOWLEDGEMENTS 
First, I would like to thank my Supervisors: Ernest Arenas, Carlos Villaescusa and Katarina Le 
Blanc. 
I would like to thank Ernest for giving me the opportunity to explore developmental biology 
as a PhD student. Thank you for sharing your knowledge, enthusiasm and always seeing the 
bright side of things and fit them in a big picture. Thanks for your trust, support and allowing 
me to freely explore new ideas. I am especially grateful for your help with the thesis until the 
very last moment. 
I would like to thank you, Carlos, for all your help and discussions about my projects, for your 
knowledge and high standard for science, and for your advices for my future career.    
 
External Collaborators  
I would like to thank Juan Antonio Sánchez-Alcañiz, Nicolas Fritz, Changgeng Peng, Per 
Uhlén and Oscar Marín for their contribution to the articles. It has been a pleasure to work with 
all of you.  
Internal Collaborators  
I would like to thank former Arenas lab members: Emma Andersson, Linda Edman, Spyros 
Theofilopoulos, Diogo Ribeiro, Lukas Cajanek, and Vitezslav Bryja, as well as to current lab 
members Carmen, Dawei, Enrique and Daniel for their help, discussions and contribution. It 
has been great to work and learn from all of you! 
Opponent and examination board 
I would like to thank Dr. Diogo S. Castro and members of examination board Drs. Finn 
Hallböök, Ana Teixeira and Lars Olson for accepting the invitation and for their participation 
in my PhD thesis defense.  
Past and present members of Arenas lab 
I would like to thank all present and past lab members: Carmen, Enrique, Dawei, Alca, Linda, 
Daniel, Karol, Kaneyasu, Chika, Pia, Geeta, Mark, Fabia, Willy, Catarina, Isabel, Kim and 
Linda Adlerz, for all the help, reagents and discussions; Lottie for your help in ordering and 
tips for living in Sweden.   
MolNeuro 
I would like to thank Patrik Ernfors, Per Uhlén, Sten Linnarsson, Gonçalo Castelo-Branco, Jens 
Hjerling-Leffler and Ulrika Marklund for making MolNeuro an excellent and unique place for 
doing science; Alessandra for all your help, especially the one with accommodation even 
before I came here; Johnny for always keeping the lab running smoothly.   
 26 
 
I would like to thank all the past and present members at MolNeuro who I got the opportunity 
to work with, for your effort to make the division such a vibrant environment. Especially I 
would like to thank: Songbai for your help since the first day I came here and for your expertise 
and dedication; Changgeng for your advices and vision in science; Satish for your suggestions, 
advices, all the talks and collaboration; Shigeaki for your expertise and many helps; Amit for 
your advice for Postdoc and for your hard working attitude and productivity; Erik for your help 
with calcium imaging and I hope something will come out; Ana M. and Carolina for help with 
in situ hybridization; Sueli for help with MAC sorting; Alessandro for your help with 
antibodies, your excellent PhD work and your advice for Postdocs; Boris for your optimistic 
attitude; Hind for being officemates long time ago; Per, Göran and Connla for running the 
CLICK facility; David for teaching me how to make sandwiches in a professional way; Gioele, 
Lars and Hannah for scientific lunch talks; Ana F. for discussion on the idea that ideas are 
cheap; Ivar for your interest in Eastern culture; Lili, Daohua, Yiwen, Dawei, Jianren, Yiqiao, 
Mingdong, Xiuzhe, Xiangyu, Zhengwen and Xiao Fei for creating a Chinese community here; 
Carmen for proofreading of the thesis. I would like to thank all the people that I have met over 
last years for your patience with my English.  
 
I would like to thank my previous supervisor Prof. Feng-yan Sun for supporting me to conduct 
PhD study at KI and for your training me in neuroscience, for your knowledge and expertise.  
 
Last but not least, I would like to thank my parents for your endless support; my wife Jie and 
my lovely son Yichen, for your support and love. 
 
  27 
5 REFERENCES 
Andersson, E., Tryggvason, U., Deng, Q., Friling, S., Alekseenko, Z., Robert, B., 
Perlmann, T. and Ericson, J. (2006a). Identification of intrinsic determinants of 
midbrain dopamine neurons. Cell 124, 393–405. 
Andersson, E., Jensen, J. B., Parmar, M., Guillemot, F. and Björklund,  a (2006b). 
Development of the mesencephalic dopaminergic neuron system is compromised in the 
absence of neurogenin 2. Development 133, 507–16. 
Andersson, E. R., Prakash, N., Cajanek, L., Minina, E., Bryja, V., Bryjova, L., 
Yamaguchi, T. P., Hall, A. C., Wurst, W. and Arenas, E. (2008). Wnt5a regulates 
ventral midbrain morphogenesis and the development of A9-A10 dopaminergic cells in 
vivo. PLoS One 3, e3517. 
Andersson, E. R., Saltó, C., Villaescusa, J. C., Cajanek, L., Yang, S., Bryjova, L., Nagy, 
I. I., Vainio, S. J., Ramirez, C., Bryja, V., et al. (2013). Wnt5a cooperates with 
canonical Wnts to generate midbrain dopaminergic neurons in vivo and in stem cells. 
Proc. Natl. Acad. Sci. U. S. A. 110, E602-10. 
Ang, S. L., Wierda,  a, Wong, D., Stevens, K. a, Cascio, S., Rossant, J. and Zaret, K. S. 
(1993). The formation and maintenance of the definitive endoderm lineage in the mouse: 
involvement of HNF3/forkhead proteins. Development 119, 1301–1315. 
Ang, S. L., Rossant, J., Ang, S. L., Rossant, J., Ang, S.-L., Wierda, A., Wong, D., 
Stevens, K. A., Cascio, S., Rossant, J., et al. (1994). HNF-3 beta is essential for node 
and notochord formation in mouse development. Cell 78, 561–74. 
Arenas, E. (2002). Stem cells in the treatment of Parkinson’s disease. Brain Res. Bull. 57, 
795–808. 
Arenas, E. (2010). Towards stem cell replacement therapies for Parkinson’s disease. 
Biochem. Biophys. Res. Commun. 396, 152–6. 
Arenas, E. (2014). Wnt signaling in midbrain dopaminergic neuron development and 
regenerative medicine for Parkinson’s disease. J. Mol. Cell Biol. 6, 42–53. 
Arenas, E., Denham, M. and Villaescusa, J. C. (2015). How to make a midbrain 
dopaminergic neuron. Development 142, 1918–36. 
Aron, L. and Klein, R. (2011). Repairing the parkinsonian brain with neurotrophic factors. 
Trends Neurosci. 34, 88–100. 
Balabanian, K., Lagane, B., Infantino, S., Chow, K. Y. C., Harriague, J., Moepps, B., 
Arenzana-Seisdedos, F., Thelen, M. and Bachelerie, F. (2005). The chemokine SDF-
1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J. 
Biol. Chem. 280, 35760–6. 
Barde, Y. A., Edgar, D. and Thoenen, H. (1982). Purification of a new neurotrophic factor 
from mammalian brain. EMBO J. 1, 549–53. 
Barker, R. A., Barrett, J., Mason, S. L., Björklund, A., Thompson, W., Björklund, A., 
Stenevi, U., Björklund, A., Dunnett, S., Stenevi, U., et al. (2013). Fetal dopaminergic 
transplantation trials and the future of neural grafting in Parkinson’s disease. Lancet. 
Neurol. 12, 84–91. 
 28 
Barker, R. A., Drouin-Ouellet, J. and Parmar, M. (2015). Cell-based therapies for 
Parkinson disease—past insights and future potential. Nat. Rev. Neurol. 11, 492–503. 
Barneda-Zahonero, B., Servitja, J. M., Badiola, N., Miñano-Molina, A. J., Fadó, R., 
Saura, C. A. and Rodríguez-Alvarez, J. (2012). Nurr1 protein is required for N-
Methyl-D-aspartic Acid (NMDA) receptor-mediated neuronal survival. J. Biol. Chem. 
287, 11351–11362. 
Bartel, D. P. and Chen, C.-Z. (2004). Opinion: Micromanagers of gene expression: the 
potentially widespread influence of metazoan microRNAs. Nat. Rev. Genet. 5, 396–400. 
Beck, K. D., Valverde, J., Alexi, T., Poulsen, K., Moffat, B., Vandlen, R. A., Rosenthal, 
A. and Hefti, F. (1995). Mesencephalic dopaminergic neurons protected by GDNF 
from axotomy-induced degeneration in the adult brain. Nature 373, 339–341. 
Beffert, U. (2004). Reelin and Cyclin-Dependent Kinase 5-Dependent Signals Cooperate in 
Regulating Neuronal Migration and Synaptic Transmission. J. Neurosci. 24, 1897–1906. 
Bertrand, N., Castro, D. S. and Guillemot, F. (2002). Proneural genes and the specification 
of neural cell types. Nat. Rev. Neurosci. 3, 517–30. 
Björklund, A. and Dunnett, S. B. (2007). Dopamine neuron systems in the brain: an update. 
Trends Neurosci. 30, 194–202. 
Bodea, G. O., Spille, J., Abe, P., Andersson, A. S., Acker-Palmer, A., Stumm, R., 
Kubitscheck, U. and Blaess, S. (2014). Reelin and CXCL12 regulate distinct migratory 
behaviors during the development of the dopaminergic system. Development 141, 661–
73. 
Boitard, M., Bocchi, R., Egervari, K., Petrenko, V., Viale, B., Gremaud, S., Zgraggen, 
E., Salmon, P. and Kiss, J. Z. (2015). Wnt Signaling Regulates Multipolar-to-Bipolar 
Transition of Migrating Neurons in the Cerebral Cortex. Cell Rep. 10, 1349–1361. 
Bonifati, V. (2014). Genetics of Parkinson’s disease â€“ state of the art, 2013. Park. Realt. 
Disord. 20, S23–S28. 
Borrell, V. and Marín, O. (2006). Meninges control tangential migration of hem-derived 
Cajal-Retzius cells via CXCL12/CXCR4 signaling. Nat. Neurosci. 9, 1284–93. 
Bracken, C. P., Gregory, P. A., Kolesnikoff, N., Bert, A. G., Wang, J., Shannon, M. F. 
and Goodall, G. J. (2008). A double-negative feedback loop between ZEB1-SIP1 and 
the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 68, 
7846–7854. 
Bradley, A., Evans, M., Kaufman, M. H. and Robertson, E. (1984). Formation of germ-
line chimaeras from embryo-derived teratocarcinoma cell lines. Nature 309, 255–6. 
Broccoli, V., Boncinelli, E. and Wurst, W. (1999). The caudal limit of Otx2 expression 
positions the isthmic organizer. Nature 401, 164–168. 
Bryja, V., Andersson, E. R., Schambony, A., Esner, M., Bryjová, L., Biris, K. K., Hall, 
A. C., Kraft, B., Cajanek, L., Yamaguchi, T. P., et al. (2009). The extracellular 
domain of Lrp5/6 inhibits noncanonical Wnt signaling in vivo. Mol. Biol. Cell 20, 924–
36. 
Busillo, J. M. and Benovic, J. L. (2007). Regulation of CXCR4 signaling. Biochim. 
  29 
Biophys. Acta 1768, 952–63. 
Čajánek, L., Ganji, R. S., Henriques-Oliveira, C., Theofilopoulos, S., Koník, P., Bryja, 
V. and Arenas, E. (2013). Tiam1 regulates the Wnt/Dvl/Rac1 signaling pathway and 
the differentiation of midbrain dopaminergic neurons. Mol. Cell. Biol. 33, 59–70. 
Chung, S., Leung, A., Han, B. S., Chang, M. Y., Moon, J. Il, Kim, C. H., Hong, S., 
Pruszak, J., Isacson, O. and Kim, K. S. (2009). Wnt1-lmx1a Forms a Novel 
Autoregulatory Loop and Controls Midbrain Dopaminergic Differentiation 
Synergistically with the SHH-FoxA2 Pathway. Cell Stem Cell 5, 646–658. 
Cong, N., Du, P., Zhang, A., Shen, F., Su, J., Pu, P., Wang, T., Zjang, J., Kang, C. and 
Zhang, Q. (2013). Downregulated microRNA-200a promotes EMT and tumor growth 
through the Wnt/??-catenin pathway by targeting the E-cadherin repressors ZEB1/ZEB2 
in gastric adenocarcinoma. Oncol. Rep. 29, 1579–1587. 
Cooper, J. A. (2013). Mechanisms of cell migration in the nervous system. J. Cell Biol. 202, 
725–734. 
Davis, G. M., Haas, M. A. and Pocock, R. (2015). MicroRNAs: Not “Fine-Tuners” but key 
regulators of neuronal development and function. Front. Neurol. 6, 1–12. 
Demyanenko, G. P., Shibata, Y. and Maness, P. F. (2001). Altered distribution of 
dopaminergic neurons in the brain of L1 null mice. Brain Res. Dev. Brain Res. 126, 21–
30. 
Deng, Q., Andersson, E., Hedlund, E., Alekseenko, Z., Coppola, E., Panman, L., 
Millonig, J. H., Brunet, J.-F., Ericson, J. and Perlmann, T. (2011). Specific and 
integrated roles of Lmx1a, Lmx1b and Phox2a in ventral midbrain development. 
Development 138, 3399–408. 
Dent, E. W., Gupton, S. L. and Gertler, F. B. (2011). The Growth Cone Cytoskeleton in 
Axon outgrowth and guidance.pdf. Cold Spring Harb. Perspect. Biol. 
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, 
F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011). Role of YAP/TAZ in 
mechanotransduction. Nature 474, 179–183. 
Dworkin, S. and Jane, S. M. (2013). Novel mechanisms that pattern and shape the 
midbrain-hindbrain boundary. Cell. Mol. Life Sci. 70, 3365–3374. 
Ebert, M. S. and Sharp, P. A. (2012). Roles for MicroRNAs in conferring robustness to 
biological processes. Cell 149, 505–524. 
Elbediwy, A., Vincent-Mistiaen, Z. I., Spencer-Dene, B., Stone, R. K., Boeing, S., 
Wculek, S. K., Cordero, J., Tan, E. H., Ridgway, R., Brunton, V. G., et al. (2016). 
Integrin signalling regulates YAP and TAZ to control skin homeostasis. Development 
143,. 
Ellis, A. L., Wang, Z., Yu, X. and Mertz, J. E. (2010). Either ZEB1 or ZEB2/SIP1 can play 
a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-
specific manner. J. Virol. 84, 6139–52. 
Eriksen, J. L., Wszolek, Z. and Petrucelli, L. (2005). Molecular pathogenesis of Parkinson 
disease. Arch. Neurol. 62, 353–7. 
 30 
Evans, M. J. and Kaufman, M. H. (1981). Establishment in culture of pluripotential cells 
from mouse embryos. Nature 292, 154–156. 
Evsyukova, I., Plestant, C. and Anton, E. S. (2013). Integrative mechanisms of oriented 
neuronal migration in the developing brain. Annu. Rev. Cell Dev. Biol. 29, 299–353. 
Falk, A., Koch, P., Kesavan, J., Takashima, Y., Ladewig, J., Alexander, M., Wiskow, O., 
Tailor, J., Trotter, M., Pollard, S., et al. (2012). Capture of neuroepithelial-like stem 
cells from pluripotent stem cells provides a versatile system for in vitro production of 
human neurons. PLoS One 7, e29597. 
Ferri, A. L. M., Lin, W., Mavromatakis, Y. E., Wang, J. C., Sasaki, H., Whitsett, J. a 
and Ang, S.-L. (2007). Foxa1 and Foxa2 regulate multiple phases of midbrain 
dopaminergic neuron development in a dosage-dependent manner. Development 134, 
2761–9. 
Findley, L. J. (2007). The economic impact of Parkinson’s disease. Park. Relat. Disord. 13, 
8–12. 
Frim, D. M., Uhler, T. a, Galpern, W. R., Beal, M. F., Breakefield, X. O. and Isacson, O. 
(1994). Implanted fibroblasts genetically engineered to produce brain-derived 
neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic 
neurons in the rat. Proc. Natl. Acad. Sci. U. S. A. 91, 5104–5108. 
Gao, B., Song, H., Bishop, K., Elliot, G., Garrett, L., English, M. A., Andre, P., 
Robinson, J., Sood, R., Minami, Y., et al. (2011). Wnt signaling gradients establish 
planar cell polarity by inducing Vangl2 phosphorylation through Ror2. Dev. Cell 20, 
163–76. 
Ge, W., He, F., Kim, K. J., Blanchi, B., Coskun, V., Nguyen, L., Wu, X., Zhao, J., Heng, 
J. I.-T., Martinowich, K., et al. (2006). Coupling of cell migration with neurogenesis 
by proneural bHLH factors. Proc. Natl. Acad. Sci. U. S. A. 103, 1319–1324. 
González-Billault, C., Del Río, J. A., Ureña, J. M., Jiménez-Mateos, E. M., Barallobre, 
M. J., Pascual, M., Pujadas, L., Simó, S., La Torre, A., Gavin, R., et al. (2005). A 
role of MAP1B in reelin-dependent neuronal migration. Cereb. Cortex 15, 1134–1145. 
Grün, D., Wang, Y.-L., Langenberger, D., Gunsalus, K. C. and Rajewsky, N. (2005). 
microRNA target predictions across seven Drosophila species and comparison to 
mammalian targets. PLoS Comput. Biol. 1, e13. 
Hanaway, J., McConnell, J. A. and Netsky, M. G. (1971). Histogenesis of the substantia 
nigra, ventral tegmental area of Tsai and interpeduncular nucleus: an autoradiographic 
study of the mesencephalon in the rat. J. Comp. Neurol. 142, 59–73. 
Heng, J. I.-T., Nguyen, L., Castro, D. S., Zimmer, C., Wildner, H., Armant, O., 
Skowronska-Krawczyk, D., Bedogni, F., Matter, J.-M., Hevner, R., et al. (2008). 
Neurogenin 2 controls cortical neuron migration through regulation of Rnd2. Nature 
455, 114–118. 
Hickey, P. and Stacy, M. (2016). Deep brain stimulation: A paradigm shifting approach to 
treat Parkinson’s disease. Front. Neurosci. 10, 1–11. 
Hiesberger, T., Trommsdorff, M., Howell, B. W., Goffinet, A., Mumby, M. C., Cooper, 
J. A. and Herz, J. (1999). Direct binding of Reelin to VLDL receptor and ApoE 
receptor 2 induces tyrosine phosphorylation of Disabled-1 and modulates tau 
  31 
phosphorylation. Neuron 24, 481–489. 
Huang, T., Xie, Z., Wang, J., Li, M., Jing, N. and Li, L. (2011). Nuclear factor of activated 
T cells (NFAT) proteins repress canonical Wnt signaling via its interaction with 
dishevelled (Dvl) protein and participate in regulating neural progenitor cell 
proliferation and differentiation. J. Biol. Chem. 286, 37399–37405. 
Hwang, D.-Y., Hong, S., Jeong, J.-W., Choi, S., Kim, H., Kim, J. and Kim, K.-S. (2009). 
Vesicular monoamine transporter 2 and dopamine transporter are molecular targets of 
Pitx3 in the ventral midbrain dopamine neurons. J. Neurochem. 111, 1202–12. 
Hyman, C., Hofer, M., Barde, Y.-A., Juhasz, M., Yancopoulos, G. D., Squinto, S. P. and 
Lindsay, R. M. (1991). BDNF is a neurotrophic factor of dopaminergic neurons of the 
substantia nigra. Nature 350, 230–232. 
Hynes, R. O. (2002). Integrins: Bidirectional, allosteric signaling machines. Cell 110, 673–
687. 
Inestrosa, N. C. and Arenas, E. (2010). Emerging roles of Wnts in the adult nervous 
system. Nat. Rev. Neurosci. 11, 77–86. 
Itoh, Y., Moriyama, Y., Hasegawa, T., Endo, T. a, Toyoda, T. and Gotoh, Y. (2013). 
Scratch regulates neuronal migration onset via an epithelial-mesenchymal transition-like 
mechanism. Nat. Neurosci. 16, 416–25. 
Jacobs, F. M. J., Smits, S. M., Noorlander, C. W., von Oerthel, L., van der Linden, A. J. 
a, Burbach, J. P. H. and Smidt, M. P. (2007). Retinoic acid counteracts developmental 
defects in the substantia nigra caused by Pitx3 deficiency. Development 134, 2673–
2684. 
Jacobs, F. M. J., van Erp, S., van der Linden, A. J. a, von Oerthel, L., Burbach, J. P. H. 
and Smidt, M. P. (2009). Pitx3 potentiates Nurr1 in dopamine neuron terminal 
differentiation through release of SMRT-mediated repression. Development 136, 531–
540. 
Jacobs, F. M. J., Veenvliet, J. V, Almirza, W. H., Hoekstra, E. J., von Oerthel, L., van 
der Linden, A. J. a, Neijts, R., Koerkamp, M. G., van Leenen, D., Holstege, F. C. P., 
et al. (2011). Retinoic acid-dependent and -independent gene-regulatory pathways of 
Pitx3 in meso-diencephalic dopaminergic neurons. Development 138, 5213–22. 
Joksimovic, M., Yun, B. a, Kittappa, R., Anderegg, A. M., Chang, W. W., Taketo, M. 
M., McKay, R. D. G. and Awatramani, R. B. (2009). Wnt antagonism of Shh 
facilitates midbrain floor plate neurogenesis. Nat. Neurosci. 12, 125–31. 
Joyner, A. L., Liu, A. and Millet, S. (2000). Otx2, Gbx2 and Fgf8 interact to position and 
maintain a mid-hindbrain organizer. Curr. Opin. Cell Biol. 12, 736–741. 
Kalia, L. V. and Lang, A. E. (2015). Parkinson’s disease. Lancet 386, 896–912. 
Kang, W.-Y., Kim, S.-S., Cho, S.-K., Kim, S., Suh-Kim, H. and Lee, Y.-D. (2010). 
Migratory defect of mesencephalic dopaminergic neurons in developing reeler mice. 
Anat. Cell Biol. 43, 241–51. 
Katsuyama, Y. and Terashima, T. (2009). Developmental anatomy of reeler mutant mouse. 
Dev. Growth Differ. 51, 271–286. 
 32 
Kawano, H., Ohyama, K., Kawamura, K. and Nagatsu, I. (1995). Migration of 
dopaminergic neurons in the embryonic mesencephalon of mice. Brain Res. Dev. Brain 
Res. 86, 101–13. 
Kele, J., Simplicio, N., Ferri, A. L. M., Mira, H., Guillemot, F., Arenas, E. and Ang, S.-
L. (2006a). Neurogenin 2 is required for the development of ventral midbrain 
dopaminergic neurons. Development 133, 495–505. 
Kele, J., Simplicio, N., Ferri, A. L. M., Mira, H., Guillemot, F., Arenas, E. and Ang, S.-
L. (2006b). Neurogenin 2 is required for the development of ventral midbrain 
dopaminergic neurons. Development 133, 495–505. 
Keller, G. M. (1995). In vitro differentiation of embryonic stem cells. Curr. Opin. Cell Biol. 
7, 862–9. 
Keller, G. (2005). Embryonic stem cell differentiation : emergence of a new era in biology 
and medicine. 1129–1155. 
Kim, J., Inoue, K., Ishii, J., Vanti, W. B., Voronov, S. V, Murchison, E., Hannon, G. and 
Abeliovich, A. (2007). A MicroRNA feedback circuit in midbrain dopamine neurons. 
Science 317, 1220–4. 
Kirkeby, A., Grealish, S., Wolf, D. a., Nelander, J., Wood, J., Lundblad, M., Lindvall, 
O. and Parmar, M. (2012). Generation of Regionally Specified Neural Progenitors and 
Functional Neurons from Human Embryonic Stem Cells under Defined Conditions. Cell 
Rep. 1, 703–714. 
Klein, C. and Westenberger, A. (2012). Genetics of Parkinson ’ s Disease. 
Knaut, H., Blader, P., Strähle, U. and Schier, A. F. (2005). Assembly of trigeminal 
sensory ganglia by chemokine signaling. Neuron 47, 653–66. 
Koch, P., Opitz, T., Steinbeck, J. a, Ladewig, J. and Brüstle, O. (2009). A rosette-type, 
self-renewing human ES cell-derived neural stem cell with potential for in vitro 
instruction and synaptic integration. Proc. Natl. Acad. Sci. U. S. A. 106, 3225–30. 
Kordower, J. H., Freeman, T. B., Snow, B. J., Vingerhoets, F. J., Mufson, E. J., 
Sanberg, P. R., Hauser, R. a, Smith, D. a, Nauert, G. M. and Perl, D. P. (1995). 
Neuropathological evidence of graft survival and striatal reinnervation after the 
transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. N. 
Engl. J. Med. 332, 1118–1124. 
Kriks, S., Shim, J.-W., Piao, J., Ganat, Y. M., Wakeman, D. R., Xie, Z., Carrillo-Reid, 
L., Auyeung, G., Antonacci, C., Buch, A., et al. (2011). Dopamine neurons derived 
from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 
480, 547–51. 
La Fata, G., Gärtner, A., Domínguez-Iturza, N., Dresselaers, T., Dawitz, J., Poorthuis, 
R. B., Averna, M., Himmelreich, U., Meredith, R. M., Achsel, T., et al. (2014). 
FMRP regulates multipolar to bipolar transition affecting neuronal migration and 
cortical circuitry. Nat. Neurosci. 17, 1693–700. 
Lambert de Rouvroit, C. and Goffinet, A. M. (2001). Neuronal migration. Mech. Dev. 105, 
47–56. 
Leibrock, J., Lottspeich, F., Hohn, A., Hofer, M., Hengerer, B., Masiakowski, P., 
  33 
Thoenen, H. and Barde, Y.-A. (1989). Molecular cloning and expression of brain-
derived neurotrophic factor. Nature 341, 149–152. 
Li, Q., Shirabe, K., Thisse, C., Thisse, B., Okamoto, H., Masai, I. and Kuwada, J. Y. 
(2005). Chemokine signaling guides axons within the retina in zebrafish. J. Neurosci. 
25, 1711–7. 
Li, G., Kataoka, H., Coughlin, S. R. and Pleasure, S. J. (2009). Identification of a transient 
subpial neurogenic zone in the developing dentate gyrus and its regulation by Cxcl12 
and reelin signaling. Development 136, 327–35. 
Lieberam, I., Agalliu, D., Nagasawa, T., Ericson, J. and Jessell, T. M. (2005). A Cxcl12-
CXCR4 chemokine signaling pathway defines the initial trajectory of mammalian motor 
axons. Neuron 47, 667–79. 
Lin, L. F., Doherty, D. H., Lile, J. D., Bektesh, S. and Collins, F. (1993). GDNF: a glial 
cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 
1130–2. 
Lindholm, D., Mäkelä, J., Di Liberto, V., Mudò, G., Belluardo, N., Eriksson, O. and 
Saarma, M. (2016). Current disease modifying approaches to treat Parkinson’s disease. 
Cell. Mol. Life Sci. 73, 1365–1379. 
Lindvall, O. and al.,  et (1989). Human fetal dopamine neurons grafted into the striatum in 
two patients with severe Parkinson’s disease. Arch. Neurol. 46, 615–631. 
Lindvall, O. and Björklund, A. (2011). Cell Therapeutics in Parkinson’s Disease. 
Neurotherapeutics 8, 539–548. 
Lindvall, O., Rehncrona, S., Gustavii, B., Brundin, P., Astedt, B., Widner, H., 
Lindholm, T., Björklund, A., Leenders, K. L., Rothwell, J. C., et al. (1988). Fetal 
dopamine-rich mesencephalic grafts in Parkinson’s disease. Lancet (London, England) 
2, 1483–4. 
López-Bendito, G., Sánchez-Alcañiz, J. A., Pla, R., Borrell, V., Picó, E., Valdeolmillos, 
M. and Marín, O. (2008). Chemokine signaling controls intracortical migration and 
final distribution of GABAergic interneurons. J. Neurosci. 28, 1613–24. 
Lorenzl, S., Albers, D. S., Narr, S., Chirichigno, J. and Beal, M. F. (2002). Expression of 
MMP-2, MMP-9, and MMP-1 and Their Endogenous Counterregulators TIMP-1 and 
TIMP-2 in Postmortem Brain Tissue of Parkinson’s Disease. Exp. Neurol. 178, 13–20. 
LoTurco, J. J. and Bai, J. (2006). The multipolar stage and disruptions in neuronal 
migration. Trends Neurosci. 29, 407–413. 
Ma, Q., Sommer, L., Cserjesi, P. and Anderson, D. J. (1997). Mash1 and neurogenin1 
expression patterns define complementary domains of neuroepithelium in the 
developing CNS and are correlated with regions expressing notch ligands. J. Neurosci. 
17, 3644–3652. 
Ma, Q., Jones, D., Borghesani, P. R., Segal, R. a, Nagasawa, T., Kishimoto, T., Bronson, 
R. T. and Springer, T. a (1998). Impaired B-lymphopoiesis, myelopoiesis, and derailed 
cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc. Natl. Acad. 
Sci. U. S. A. 95, 9448–53. 
Marín, O., Valiente, M., Ge, X. and Tsai, L.-H. (2010). Guiding neuronal cell migrations. 
 34 
Cold Spring Harb. Perspect. Biol. 2, a001834. 
Martin, G. R. (1981). Isolation of a pluripotent cell line from early mouse embryos cultured 
in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A 78, 
7634–7638. 
Martin, K., Pritchett, J., Llewellyn, J., Mullan, A. F., Athwal, V. S., Dobie, R., Harvey, 
E., Zeef, L., Farrow, S., Streuli, C., et al. (2016). PAK proteins and YAP-1 signalling 
downstream of integrin beta-1 in myofibroblasts promote liver fibrosis. Nat. Commun. 7, 
12502. 
Mélik-Parsadaniantz, S. and Rostène, W. (2008). Chemokines and neuromodulation. J. 
Neuroimmunol. 198, 62–8. 
Metzakopian, E., Lin, W., Salmon-Divon, M., Dvinge, H., Andersson, E., Ericson, J., 
Perlmann, T., Whitsett, J. a, Bertone, P. and Ang, S.-L. (2012). Genome-wide 
characterization of Foxa2 targets reveals upregulation of floor plate genes and repression 
of ventrolateral genes in midbrain dopaminergic progenitors. Development 139, 2625–
34. 
Metzakopian, E., Bouhali, K., Alvarez-Saavedra, M., Whitsett, J. a., Picketts, D. J. and 
Ang, S.-L. (2015). Genome-wide characterisation of Foxa1 binding sites reveals several 
mechanisms for regulating neuronal differentiation in midbrain dopamine cells. 
Development 142, 1315–1324. 
Miller, R. L., James-Kracke, M., Sun, G. Y. and Sun, A. Y. (2009). Oxidative and 
inflammatory pathways in Parkinson’s disease. Neurochem. Res. 34, 55–65. 
Millet, S., Campbell, K., Epstein, D. J., Losos, K., Harris, E. and Joyner,  a L. (1999). A 
role for Gbx2 in repression of Otx2 and positioning the mid/hindbrain organizer. Nature 
401, 161–164. 
Mithal, D. S., Banisadr, G. and Miller, R. J. (2012). CXCL12 signaling in the development 
of the nervous system. J. Neuroimmune Pharmacol. 7, 820–34. 
Miyasaka, N., Knaut, H. and Yoshihara, Y. (2007). Cxcl12/Cxcr4 chemokine signaling is 
required for placode assembly and sensory axon pathfinding in the zebrafish olfactory 
system. Development 134, 2459–68. 
Miyata, T., Kawaguchi, A., Okano, H. and Ogawa, M. (2001). Asymmetric inheritance of 
radial glial fibers by cortical neurons. Neuron 31, 727–741. 
Mueller, W., Schütz, D., Nagel, F., Schulz, S. and Stumm, R. (2013). Hierarchical 
organization of multi-site phosphorylation at the CXCR4 C terminus. PLoS One 8, 
e64975. 
Murry, C. E. and Keller, G. (2008). Differentiation of Embryonic Stem Cells to??Clinically 
Relevant Populations: Lessons from Embryonic Development. Cell 132, 661–680. 
Nadarajah, B. and Parnavelas, J. G. (2002). Modes of neuronal migration in the 
developing cerebral cortex. Nat. Rev. Neurosci. 3, 423–32. 
Nakatani, T., Kumai, M., Mizuhara, E., Minaki, Y. and Ono, Y. (2010). Lmx1a and 
Lmx1b cooperate with Foxa2 to coordinate the specification of dopaminergic neurons 
and control of floor plate cell differentiation in the developing mesencephalon. Dev. 
Biol. 339, 101–13. 
  35 
Niehrs, C. (2012). The complex world of WNT receptor signalling. Nat. Rev. Mol. Cell Biol. 
13, 767–779. 
Nishikawa, S., Goto, S., Yamada, K., Hamasaki, T. and Ushio, Y. (2003). Lack of Reelin 
causes malpositioning of nigral dopaminergic neurons: evidence from comparison of 
normal and Reln(rl) mutant mice. J. Comp. Neurol. 461, 166–73. 
Noctor, S. C., Flint, A. C., Weissman, T. A., Dammerman, R. S. and Kriegstein, A. R. 
(2001). Neurons derived from radial glial cells establish radial units in neocortex. Nature 
409, 714–720. 
Odemis, V., Lamp, E., Pezeshki, G., Moepps, B., Schilling, K., Gierschik, P., Littman, D. 
R. and Engele, J. (2005). Mice deficient in the chemokine receptor CXCR4 exhibit 
impaired limb innervation and myogenesis. Mol. Cell. Neurosci. 30, 494–505. 
Ohyama, K., Kawano, H., Asou, H., Fukuda, T., Oohira,  a, Uyemura, K. and 
Kawamura, K. (1998). Coordinate expression of L1 and 6B4 proteoglycan/phosphacan 
is correlated with the migration of mesencephalic dopaminergic neurons in mice. Brain 
Res. Dev. Brain Res. 107, 219–26. 
Pacary, E., Heng, J., Azzarelli, R., Riou, P., Castro, D., Lebel-Potter, M., Parras, C., 
Bell, D. M., Ridley, A. J., Parsons, M., et al. (2011). Proneural transcription factors 
regulate different steps of cortical neuron migration through rnd-mediated inhibition of 
RhoA signaling. Neuron 69, 1069–1084. 
Pan, D. (2010). The hippo signaling pathway in development and cancer. Dev. Cell 19, 491–
505. 
Paredes, M. F., Li, G., Berger, O., Baraban, S. C. and Pleasure, S. J. (2006). Stromal-
derived factor-1 (CXCL12) regulates laminar position of Cajal-Retzius cells in normal 
and dysplastic brains. J. Neurosci. 26, 9404–12. 
Park, H. T., Wu, J. and Rao, Y. (2002). Molecular control of neuronal migration. Bioessays 
24, 821–7. 
Park, S. M., Gaur, A. B., Lengyel, E. and Peter, M. E. (2008). The miR-200 family 
determines the epithelial phenotype of cancer cells by targeting the E-cadherin 
repressors ZEB1 and ZEB2. Genes Dev. 22, 894–907. 
Pasquinelli, A. E. (2012). MicroRNAs and their targets: recognition, regulation and an 
emerging reciprocal relationship. Nat. Rev. Genet. 13, 271–82. 
Peng, C., Aron, L., Klein, R., Li, M., Wurst, W., Prakash, N. and Le, W. (2011). Pitx3 is 
a critical mediator of GDNF-induced BDNF expression in nigrostriatal dopaminergic 
neurons. J. Neurosci. 31, 12802–15. 
Peng, C., Li, N., Ng, Y.-K., Zhang, J., Meier, F., Theis, F. J., Merkenschlager, M., Chen, 
W., Wurst, W. and Prakash, N. (2012). A unilateral negative feedback loop between 
miR-200 microRNAs and Sox2/E2F3 controls neural progenitor cell-cycle exit and 
differentiation. J. Neurosci. 32, 13292–308. 
Petri, R., Malmevik, J., Fasching, L., Åkerblom, M. and Jakobsson, J. (2014). miRNAs 
in brain development. Exp. Cell Res. 321, 84–89. 
Politis, M. and Lindvall, O. (2012). Clinical application of stem cell therapy in Parkinson’s 
disease. BMC Med. 10, 1. 
 36 
Politis, M., Wu, K., Loane, C., Quinn, N. P., Brooks, D. J., Rehncrona, S., Bjorklund, 
A., Lindvall, O. and Piccini, P. (2010). Serotonergic neurons mediate dyskinesia side 
effects in Parkinson’s patients with neural transplants. Sci. Transl. Med. 2, 38ra46. 
Prakash, N., Brodski, C., Naserke, T., Puelles, E., Gogoi, R., Hall, A., Panhuysen, M., 
Echevarria, D., Sussel, L., Weisenhorn, D. M. V., et al. (2006). A Wnt1-regulated 
genetic network controls the identity and fate of midbrain-dopaminergic progenitors in 
vivo. Development 133, 89–98. 
Puelles, E., Annino, A., Tuorto, F., Usiello, A., Acampora, D., Czerny, T., Brodski, C., 
Ang, S.-L. L., Wurst, W. and Simeone, A. (2004). Otx2 regulates the extent, identity 
and fate of neuronal progenitor domains in the ventral midbrain. Development 131, 
2037–48. 
Reiss, K., Mentlein, R., Sievers, J. and Hartmann, D. (2002). Stromal cell-derived factor 1 
is secreted by meningeal cells and acts as chemotactic factor on neuronal stem cells of 
the cerebellar external granular layer. Neuroscience 115, 295–305. 
Rhinn, M., Dierich,  a, Shawlot, W., Behringer, R. R., Le Meur, M. and Ang, S. L. 
(1998). Sequential roles for Otx2 in visceral endoderm and neuroectoderm for forebrain 
and midbrain induction and specification. Development 125, 845–856. 
Rice, D. S. and Curran, T. (1999). Mutant mice with scrambled brains: Understanding the 
signaling pathways that control cell positioning in the CNS. Genes Dev. 13, 2758–2773. 
Sacchetti, P., Sousa, K. M., Hall, A. C., Liste, I., Steffensen, K. R., Theofilopoulos, S., 
Parish, C. L., Hazenberg, C., Richter, L. A., Hovatta, O., et al. (2009). Liver X 
receptors and oxysterols promote ventral midbrain neurogenesis in vivo and in human 
embryonic stem cells. Cell Stem Cell 5, 409–19. 
Sánchez-Alcañiz, J. A., Haege, S., Mueller, W., Pla, R., Mackay, F., Schulz, S., López-
Bendito, G., Stumm, R. and Marín, O. (2011). Cxcr7 controls neuronal migration by 
regulating chemokine responsiveness. Neuron 69, 77–90. 
Sánchez-Tilló, E., Siles, L., de Barrios, O., Cuatrecasas, M., Vaquero, E. C., Castells, A. 
and Postigo, A. (2011). Expanding roles of ZEB factors in tumorigenesis and tumor 
progression. Am. J. Cancer Res. 1, 897–912. 
Sapède, D., Rossel, M., Dambly-Chaudière, C. and Ghysen, A. (2005). Role of SDF1 
chemokine in the development of lateral line efferent and facial motor neurons. Proc. 
Natl. Acad. Sci. U. S. A. 102, 1714–8. 
Sasaki, H., Hui, C., Nakafuku, M. and Kondoh, H. (1997). A binding site for Gli proteins 
is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to 
Shh in vitro. Development 124, 1313–22. 
Sharaf, A., Rahhal, B., Spittau, B. and Roussa, E. (2015). Localization of reelin signaling 
pathway components in murine midbrain and striatum. Cell Tissue Res. 359, 393–407. 
Shults, C. W., Hashimoto, R., Brady, R. M. and Gage, F. H. (1990). Dopaminergic cells 
align along radial glia in the developing mesencephalon of the rat. Neuroscience 38, 
427–36. 
Singleton, A. and Hardy, J. (2016). The Evolution of Genetics: Alzheimer’s and 
Parkinson’s Diseases. Neuron 90, 1154–1163. 
  37 
Smidt, M. P., Asbreuk, C. H., Cox, J. J., Chen, H., Johnson, R. L. and Burbach, J. P. 
(2000). A second independent pathway for development of mesencephalic dopaminergic 
neurons requires Lmx1b. Nat. Neurosci. 3, 337–41. 
Smith, A. G. (2001). Embryo-derived stem cells: of mice and men. Annu. Rev. Cell Dev. 
Biol. 17, 435–62. 
Smulders, K., Dale, M., Carlson-Kutha, P., Nutt, J. and Horak FB (2016). 
Pharmacological treatment in Parkinson’s disease: Effects on gait. - PubMed - NCBI. 
Park. Relat. Disord. 16, 30263–2. 
Stiles, B., Groszer, M., Wang, S., Jiao, J. and Wu, H. (2004). PTENless means more. Dev. 
Biol. 273, 175–184. 
Stott, S. R. W., Metzakopian, E., Lin, W., Kaestner, K. H., Hen, R. and Ang, S.-L. 
(2013). Foxa1 and foxa2 are required for the maintenance of dopaminergic properties in 
ventral midbrain neurons at late embryonic stages. J. Neurosci. 33, 8022–34. 
Stumm, R. and Höllt, V. (2007). CXC chemokine receptor 4 regulates neuronal migration 
and axonal pathfinding in the developing nervous system: implications for neuronal 
regeneration in the adult brain. J. Mol. Endocrinol. 38, 377–82. 
Stumm, R., Kolodziej, A., Schulz, S., Kohtz, J. D. and Höllt, V. (2007). Patterns of SDF-
1alpha and SDF-1gamma mRNAs, migration pathways, and phenotypes of CXCR4-
expressing neurons in the developing rat telencephalon. J. Comp. Neurol. 502, 382–99. 
Tahinci, E., Thorne, C. A., Franklin, J. L., Salic, A., Christian, K. M., Lee, L. A., Coffey, 
R. J. and Lee, E. (2007). Lrp6 is required for convergent extension during Xenopus 
gastrulation. Development 134,. 
Tailor, J., Kittappa, R., Leto, K., Gates, M., Borel, M., Paulsen, O., Spitzer, S., 
Karadottir, R. T., Rossi, F., Falk, A., et al. (2013). Stem cells expanded from the 
human embryonic hindbrain stably retain regional specification and high neurogenic 
potency. J. Neurosci. 33, 12407–22. 
Tang, M., Miyamoto, Y. and Huang, E. J. (2009). Multiple roles of beta-catenin in 
controlling the neurogenic niche for midbrain dopamine neurons. Development 136, 
2027–38. 
Tansey, M. G., McCoy, M. K. and Frank-Cannon, T. C. (2007). Neuroinflammatory 
mechanisms in Parkinson’s disease: potential environmental triggers, pathways, and 
targets for early therapeutic intervention. Exp. Neurol. 208, 1–25. 
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., 
Marshall, V. S. and Jones, J. M. (1998). Embryonic stem cell lines derived from 
human blastocysts. Science 282, 1145–7. 
Tiveron, M.-C., Rossel, M., Moepps, B., Zhang, Y. L., Seidenfaden, R., Favor, J., König, 
N. and Cremer, H. (2006). Molecular interaction between projection neuron precursors 
and invading interneurons via stromal-derived factor 1 (CXCL12)/CXCR4 signaling in 
the cortical subventricular zone/intermediate zone. J. Neurosci. 26, 13273–8. 
Tomac,  a, Lindqvist, E., Lin, L. F., Ogren, S. O., Young, D., Hoffer, B. J. and Olson, L. 
(1995). Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. 
Nature 373, 335–339. 
 38 
Trommsdorff, M., Borg, J. P., Margolis, B. and Herz, J. (1998). Interaction of cytosolic 
adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor 
protein. J. Biol. Chem. 273, 33556–60. 
Valiente, M. and Marín, O. (2010). Neuronal migration mechanisms in development and 
disease. Curr. Opin. Neurobiol. 20, 68–78. 
Van Den Eeden, S. K., Tanner, C. M., Bernstein, A. L., Fross, R. D., Leimpeter, A., 
Bloch, D. a and Nelson, L. M. (2003). Incidence of Parkinson’s disease: variation by 
age, gender, and race/ethnicity. Am. J. Epidemiol. 157, 1015–1022. 
Varelas, X., Wrana, J. L., Ashe, H. L., Briscoe, J., Cockburn, K., Rossant, J., Mayor, R., 
Carmona-Fontaine, C., Harvey, K. F., al.,  et, et al. (2012). Coordinating 
developmental signaling: novel roles for the Hippo pathway. Trends Cell Biol. 22, 88–
96. 
Vaswani, A. R. and Blaess, S. (2016). Reelin Signaling in the Migration of Ventral Brain 
Stem and Spinal Cord Neurons. Front. Cell. Neurosci. 10, 62. 
Verhagen Metman, L., Pal, G. and Slavin, K. (2016). Surgical Treatment of Parkinson’s 
Disease. Curr. Treat. Options Neurol. 18, 49. 
Wallén A,  a, Castro, D. S., Zetterström, R. H., Karlén, M., Olson, L., Ericson, J. and 
Perlmann, T. (2001). Orphan nuclear receptor Nurr1 is essential for Ret expression in 
midbrain dopamine neurons and in the brain stem. Mol. Cell. Neurosci. 18, 649–663. 
Ward, M. E. and Rao, Y. (2005). Investigations of neuronal migration in the central nervous 
system. Methods Mol. Biol. 294, 137–56. 
Wassarman, K. M., Lewandoski, M., Campbell, K., Joyner, A. L., Rubenstein, J. L., 
Martinez, S., Martin, G. R., Abbott, L., Jacobowitz, D., Acampora, D., et al. (1997). 
Specification of the anterior hindbrain and establishment of a normal mid/hindbrain 
organizer is dependent on Gbx2 gene function. Development 124, 2923–34. 
Weinstein, D. C., Ruiz i Altaba, A., Chen, W. S., Hoodless, P., Prezioso, V. R., Jessell, T. 
M., Darnell, J. E., Ang, S. L., Rossant, J., Ang, S. L., et al. (1994). The winged-helix 
transcription factor HNF-3 beta is required for notochord development in the mouse 
embryo. Cell 78, 575–88. 
Wijeyekoon, R. and Barker, R. a (2009). Cell replacement therapy for Parkinson’s disease. 
Biochim. Biophys. Acta 1792, 688–702. 
Winter, J., Jung, S., Keller, S., Gregory, R. I. and Diederichs, S. (2009). Many roads to 
maturity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 11, 228–
234. 
Wong, K., Ren, X. R., Huang, Y. Z., Xie, Y., Liu, G., Saito, H., Tang, H., Wen, L., 
Brady-Kalnay, S. M., Mei, L., et al. (2001). Signal transduction in neuronal migration: 
Roles of GTPase activating proteins and the small GTPase Cdc42 in the Slit-Robo 
pathway. Cell 107, 209–221. 
Wong, K.-F., Liu, A. M., Hong, W., Xu, Z. and Luk, J. M. (2016). Integrin α2β1 inhibits 
MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling 
in hepatocellular carcinoma. Oncotarget 5,. 
Wurst, W. and Bally-Cuif, L. (2001). Neural plate patterning: upstream and downstream of 
  39 
the isthmic organizer. Nat Rev Neurosci 2, 99–108. 
Xu, B., Goldman, J. S., Rymar, V. V., Forget, C., Lo, P. S., Bull, S. J., Vereker, E., 
Barker, P. a., Trudeau, L. E., Sadikot,  a. F., et al. (2010). Critical Roles for the 
Netrin Receptor Deleted in Colorectal Cancer in Dopaminergic Neuronal Precursor 
Migration, Axon Guidance, and Axon Arborization. Neuroscience 169, 932–949. 
Yang, S., Edman, L. C., Sánchez-Alcañiz, J. A., Fritz, N., Bonilla, S., Hecht, J., Uhlén, 
P., Pleasure, S. J., Villaescusa, J. C., Marín, O., et al. (2013). Cxcl12/Cxcr4 signaling 
controls the migration and process orientation of A9-A10 dopaminergic neurons. 
Development 140, 4554–64. 
Yang, P., Pavlovic, D., Waldvogel, H., Dragunow, M., Synek, B., Turner, C., Faull, R. 
and Guan, J. (2015). String Vessel Formation is Increased in the Brain of Parkinson 
Disease. J. Parkinsons. Dis. 5, 821–836. 
Ypsilanti, A. R., Zagar, Y. and Chédotal, A. (2010). Moving away from the midline: new 
developments for Slit and Robo. Development 137, 1939–52. 
Yu, F.-X., Zhao, B., Panupinthu, N., Jewell, J. L., Lian, I., Wang, L. H., Zhao, J., Yuan, 
H., Tumaneng, K., Li, H., et al. (2012). Regulation of the Hippo-YAP pathway by G-
protein-coupled receptor signaling. Cell 150, 780–91. 
Zetterström, R. H., Solomin, L., Jansson, L., Hoffer, B. J., Olson, L. and Perlmann, T. 
(1997). Dopamine neuron agenesis in Nurr1-deficient mice. Science 276, 248–50. 
Zhao, B., Zhao, B., Wei, X., Wei, X., Li, W., Li, W., Udan, R. S., Udan, R. S., Yang, Q., 
Yang, Q., et al. (2007). Inactivation of YAP oncoprotein by the Hippo pathway is 
involved in cell contact inhibition and tissue growth control. Genes Dev. 21, 2747–2761. 
Zhou, X., Wang, Z., Huang, W. and Lei, Q. Y. (2014). G protein-coupled receptors: 
Bridging the gap from the extracellular signals to the Hippo pathway. Acta Biochim. 
Biophys. Sin. (Shanghai). 47, 10–15. 
Zhu, Y. and Murakami, F. (2012). Chemokine CXCL12 and its receptors in the developing 
central nervous system: emerging themes and future perspectives. Dev. Neurobiol. 72, 
1349–62. 
Zhu, Y., Yu, T., Zhang, X.-C., Nagasawa, T., Wu, J. Y. and Rao, Y. (2002). Role of the 
chemokine SDF-1 as the meningeal attractant for embryonic cerebellar neurons. Nat. 
Neurosci. 5, 719–20. 
Zlotnik, A. and Yoshie, O. (2012). Review The Chemokine Superfamily Revisited. 
Immunity 36, 705–716. 
 
